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ABSTRACT 
 
This study was designed to explore the rationale of using trastuzumab 
(TmAb) tailored docetaxel (Doc) loaded poly-D, L-lactide-co-glycolide (PLGA) 
nanoparticles (NPs) to target the human epidermal receptor-2 (HER2) receptors of 
breast cancer cells. Utilizing emulsification solvent evaporation technique, pre-
activated drug loaded NPs were prepared by embedding a homo bi-functional 
spacer, bis(sulfosuccinimidyl) suberate (BS3) non-covalently onto the NP surface. 
Freeze-dried pre-activated NPs were then decorated with TmAb followed by one 
step covalent attachment method. Prepared NPs were characterized for size, surface 
charge, polydispersity index (PDI), drug loading, drug entrapment efficiency, and 
antibody (Ab) quantification. All the results after physicochemical characterization 
were found in a desired range. The covalent attachment between TmAb and BS3 
embedded NPs was confirmed by both Fourier transform infrared (FTIR) 
spectroscopy and Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE). Quantitative assay was performed to measure the amount of TmAb 
attached per mg of NPs.  
In vitro cell uptake studies were evaluated for fluorescent coumarin-6 
(Coum-6) dye instead of drug loaded into the PLGA NPs with flow cytometry and 
confocal microscopy. Higher cellular uptake was resulted for Ab decorated NPs in 
both cell types which support the potential use of this formulation strategy as a 
targeted chemotherapeutic drug delivery system against HER2 positive breast 
cancer. Cell uptake of Coum-6 loaded NPs of different formulations was also 
observed after preincubation of both cell lines to investigate the targeting efficiency 
 iii 
of the TmAb. Preincubation of HER2 overexpressed SKBR-3 cells with TmAb 
demonstrated a significant reduction in cellular uptake of Coum-6 loaded TmAb 
modified NPs.  
The level of HER2 expression was assessed for the targeted NPs comparing 
other NP formulations, free Doc, filtered TmAb, and Herceptin
®
 by flow cytometry, 
Western blot, and fluorescence microscopy. Relative HER2 expression levels were 
observed for all treatment groups, however HER2 expression was lower after 
treating the cells with TmAb modified Doc loaded NPs. 
To explore the possible reasons of reduced HER2 expression and 
chemotherapeutic responses, cell viability and apoptosis study were considered after 
treating both cell lines with the formulations. Apoptosis studies revealed the 
chemotherapeutic responses for different formulations to the HER2 overexpressed 
and moderate expressed cell lines. 
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1. INTRODUCTION 
 
Cancer remains one of the most ominous diseases that is complex and 
difficult to treat. Conventional chemotherapies have been widely used to treat 
cancerous diseases along with other therapies although they are limited due to 
unavoidable side-effects (1). In recent years, chemotherapeutic drug loaded 
biodegradable nanoparticles (NPs) have been found with substantial potential to 
offer some model solution for the main limitations of conventional chemotherapies 
such as non-specificity, multiple drug resistances. Nevertheless, the reduced 
localization and insufficient selectivity of drug loaded NPs for desired tumor cells 
were reported with inadequate efficacies for effective chemotherapeutic responses. 
To overcome the limitations, targeted chemotherapy has been well accepted concept 
to design an effective targeted drug delivery system which can carry the 
chemotherapeutic agent to desired tumor cells without affecting normal healthy 
cells. 
Overexpression of certain proteins called tumor antigens often takes place for 
some cancers’ progression. HER2 is one of those tumor antigens which have been 
reported with overexpression in 25-30% of all breast cancer types in women (2). In 
addition, the overexpression of HER2 is a key pathological biomarker to diagnose 
early stage breast cancer. Targeting such tumor antigens with a suitable ligand has 
been reported most often in the literature for the development of ideal targeted drug 
delivery systems for HER2 positive breast cancer. 
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FDA approved humanized mAb; Trastuzumab (Herceptin
®
) (TmAb) is 
clinically recommended option for treating the HER2 overexpressed breast cancer. 
In some cases, enhanced synergistic clinical effects of TmAb have been reported 
while using with the first-line chemotherapy for metastatic breast cancer (3). Hence, 
the arrangement for combination of TmAb and chemotherapeutic agents utilizing 
nano-drug delivery system for treating HER2 positive breast cancer has been 
proposed as reasonable means of targeted chemotherapy. To achieve this goal, 
docetaxel (Doc) has become a most common chemotherapeutic drug of choice for 
breast cancer due to some benefits over the other taxans members (4). In addition, 
biodegradable US FDA approved PLGA NPs have been emerged as an effective 
drug delivery system for use in humans (5). The purpose of using polymeric NPs for 
designing of targeted chemotherapy have been well reported for three major reasons 
namely; a) the large surface area of NPs for functionalization convenience, b) 
controlled therapeutic efficacy, and c) the ease capacities to load most anti-cancer 
drugs (6). However, practical tailoring of receptor specific ligand to the surface of 
drug loaded PLGA NPs has not been established with perfect progression.  
To achieve the predicted ligand-receptor binding for NPs depot into the 
tumor cell, surface functionalization of NPs with ligand is a required condition. To 
execute this pre-requisite condition, several processes have been adduced to 
conjugate the ligand to the NPs with or without using cross linking agents (7). There 
are mainly two types of cross linking agents such as homo-bi-functional and hetero-
bi-functional agents that can be used depending on the reactive group at the end of 
the spacer arm that is required. A homo-bi-functional spacer, bis-sulfosuccinimidyl 
suberate (BS3) has been used to develop a cross link between Ab and NPs by 
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forming covalent amide bond. Utilizing emulsification and solvent evaporation 
technique, BS3 was pre-embedded onto the surface of NPs before the covalent 
attachment (8). The reaction mechanism involves the release of terminal sulpho-
NHS group from both end sides of the spacer to form an amide bond between the 
carboxylic group of BS3 and the lysine group of TmAb. This covalent amide bond 
formation is a simple one step stable attachment process without any modification of 
either spacer or targeting Ab. 
Moreover, targeted tumor cell specific chemotherapeutic delivery using NPs 
has grown in importance since the cytotoxic drugs can concentrate only in the cancer 
cells which subsequently yield enhanced therapeutic effects with reduced side 
effects. Upon attachment of targeted ligand of NPs to the specific tumor antigen of 
cell, the particles can thus, ideally, are internalized into the cells through uptake and 
keep the chemotherapeutic payload away from plasma exposure. Therefore, the 
chemotherapeutic drug inside the NPs can be released inside the cell membrane 
through endosomal or lysosomal degradation. As a result, releasing the drug 
throughout the cell cytoplasm is able to kill the desired tumor cell and stop further 
tumor proliferation. 
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2. LITERATURE REVIEW 
 
2.1. Overview: HER2 overexpressed breast cancer 
In most cases, cancer takes place when genetic material is damaged or 
altered. This genetic alteration causes abnormal activities and unregulated 
proliferation of cells in the body. For rapid proliferation, cancerous cells require 
more nutrient supply than normal cells. Being in competition for sufficient nutrient 
supply, normal cells get displaced by the tumor cells resulting in uncontrolled cell 
division (9). Cancer remains one of the most prevalent and predominant diseases 
causing death. More than 10 million people per year are diagnosed with cancer 
disease worldwide (10). Breast cancer is rated as the second leading cause of cancer 
deaths among all invasive cancers in women (11) (12). Around 25-30% of all types 
of breast cancers are found to be associated with the overexpression of one of the 
epidermal growth factor receptors HER2. HER2 is a key biomarker for the 
pathogenesis of earlier stage breast cancer and exhibits an opportunity to design 
anticancer based targeted drug delivery system (13). However, no specific symptoms 
are notable at the initial stages of breast cancer in women and HER2 screening test is 
one of the common diagnosis processes to identify the disease (14). 
 
2.2. Conventional therapies for breast cancer 
Currently surgery, radiation therapy, hormone therapy, immunotherapy and 
chemotherapy are well established as common effective treatment options to tackle 
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the overall breast cancer. However, these traditional cancer therapies have a number 
of drawbacks and limitations (15). Research has been successful in developing 
treatment options with antibodies that impede breast cancer cell growth (16, 17). 
Chemotherapy is a more common breast cancer therapy where cytotoxic drugs 
interfere with the cellular processes in a nonspecific manner (18). However, normal 
healthy tissues are inevitably exposed to these chemotherapeutic agents leading to 
adverse drug effects (19). Poor bioavailability of high molecular weight 
chemotherapeutic agents and multiple drug resistance are two of the most important 
drawbacks of chemotherapy (20). Inefficient and non-selective drug delivery can 
lead to the development of drug resistance. Additionally drug entry (influx and 
efflux), metabolic alteration, drug sequestration or repossession, disruption of 
apoptotic pathways, alteration of signal transduction pathways, microenvironment 
and activation of DNA repair mechanisms are also responsible for the manifestation 
and development of drug resistance (21). To overcome these limitations, more 
effective site-specific drug delivery systems need to be developed, which can 
significantly improve the efficacy of the therapeutic agent with minimal toxicity. To 
advance research towards this goal, nanotechnology has attracted considerable 
attention from the researchers to establish the synthesis of nano scale biodegradable 
drug carriers that can specifically target tumor sites (22).  
 
2.3. Role of HER2 in targeting 
The transmembrane HERs play a key role in transmission of cell signals 
regulating cell growth and proliferation. This receptor family is comprised of four 
homologous members including HER1, HER2, HER3 and HER4. Among these, 
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only HER2 does not have an identifiable ligand for its extracellular domain (23). 
The HER2 receptor (also known as Neu, ErbB2, CD340 or cluster of differentiation 
340, p185 or 185-kDa plasma membrane phosphoprotein) is a transmembrane 
glycoprotein encoded by ErbB2 gene on the long arm of chromosome-17 in humans 
(24). Structurally, HER2 has three parts including the N-terminal cysteine rich 
extracellular domain (ECD), a single α-helix transmembrane lipophilic domain and 
an intracellular tyrosine kinase domain in cytoplasmic sites (25). HER2 receptor’s 
dimerization depends on the binding of selective ligands with its ECD while a 
conformational change occurs. As a result of dimerization, this conformational 
change activates the cytoplasmic catalytic function, which in turn 
autophosphorylates the tyrosine residues within the cytoplasmic domain of the 
receptor. The induced autophosphorylation initiates a complex variety of signal 
transduction pathways (figure-2.1) (26-28).  
 
 
 
 
 
 
 
 
Figure-2.1: HER2 signaling pathways (26-28) 
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Although HER2 regulates cell development stages in normal cells, signaling 
of HER2 through various pathways stimulates cell proliferation and blood vessel 
growth to nourish tumor angiogenesis as well as to induce metastasis. The common 
mechanism of HER2 protein overexpression due to increased HER2 protein 
synthesis is associated with HER2 gene amplification and transcriptional 
dysregulation. This overexpressed HER2 protein concentration results in the 
activation of HER2 dimerization in the absence of ligand binding leading to 
uncontrolled cell proliferation and tumorigenic transformation (29). During normal 
cell growth, HER2 receptor is expressed at normal levels; but in cancerous cells, 
overexpression of HER2 receptors occurs. This overexpression facilitates free 
ligands to bind with excessive HER2 receptors to become preferential heterodimers 
for other HER receptors. These ‘preferential’ heterodimers have long survival on the 
cell surface, which induces enhanced transduction signaling and high malignant 
survival growth (30). Monoclonal antibodies (mAb) have been employed as an 
effective active targeted therapy since these antibodies can specifically recognize the 
overexpressed HER2 positive tumor cells and internalize through receptor mediated 
endocytosis (13, 31). 
 
2.4. Strategic principles of targeting HER2 receptor 
For effective cancer treatment with minimum side effects, anticancer drugs 
have to localize at selective tumor cells without losing its therapeutic properties 
during the systemic circulation and thus able to kill the tumor cells without 
interfering with the normal cells. Ideally, the principle of targeted anti-cancer 
therapy is based on active targeting (32). Cellular recognition in molecular level is 
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able to target the tumor cell actively by ligand-receptor, antigen-antibody 
interactions, and aptamers. Active targeting of therapeutic drug can be accomplished 
by coupling drug or nano-carrier with cell specific targeting moiety. These targeting 
moieties consist of specific affinity for the receptors or antigens on the cell surface. 
The level of such antigen expression can be employed as a tool to differentiate 
between tumor and normal cells (33). However, to formulate more effective tumor 
specific delivery system, some important factors should be optimized carefully such 
as – 
i) the receptor or antigen on the surface of cell should be 
entirely expressed on the tumor cells rather than normal 
cells,  
ii) expression on all the targeted tumor cells should be 
consistent,  
iii) the receptor or antigen on the cell surface should not be shed 
into the systemic circulation. 
In addition, selecting suitable targeting ligand is a major criterion to achieve 
the maximum internalization property of targeted conjugates after binding to the 
target cells. Internalization mechanism is defined as the process of high 
accumulation of drug into the tumor cells after recycling of the receptor or antigen 
back onto the cancer cells for second round of drug transport by binding with the 
same new receptor targeted conjugates (9) (34) (35). 
Active targeting through ligand-receptor interaction includes some possible 
pathways such as lectin-carbohydrate interaction, transferrin receptor, folate 
receptor, human epidermal growth factor (EGF) receptor, and finally peptide 
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receptor (36). A mitogenic protein of human body is well known as EGF receptor 
associated with cellular mechanism such as cell division, transcription, and growth. 
Expression of one EGF receptor (HER2) occurs on the surface of tumor cells 100 
times more than normal cells, which is more pronounced marker for a variety of 
human cancers such as lung, prostate, and breast cancer. Drug delivery system 
conjugated by anti-HER2 ligand can be an effective way for targeting cancer cell 
(37) (38). However, body can distinguish such drug carrier-conjugates as foreign 
substances, which are taken by the liver and spleen from the blood stream through 
reticulo-endothelial system (RES) (39). In order to escape the mononuclear 
phagocytosis, surface functionalization and enhanced hydrophilicity of nano drug 
carriers can be considered as the primary requirements. Because, the enhanced half-
life of the nano-carriers during the systemic circulation is prerequisite for maximum 
binding between the specific cell surface receptors and the ligands of NPs towards 
active localization (40) (41) (42). In addition, NP attached humanized mAb can be 
distinguished as body’s own components to hide the NPs from RES.   
 
2.5. Components for designing HER2 targeted anticancer drug loaded NP 
An ideal anti-HER2 receptor specific targeted anticancer drug loaded NP can 
be designed by combining the following components as described in the figure-2.2. 
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Figure-2.2: Different components for designing anti-HER2 targeted cytotoxic drug loaded 
carrier 
 
2.5.1. Targeting ligand: Trastuzumab 
A number of monoclonal antibodies have already been approved by FDA for 
targeted cancer treatment which can be utilized to target respective EGF ligand. To 
identify and target the antigenic epitope on the ECD of HER2 receptor, a humanized 
IgG1 mAb named Trastuzumab (TmAb) has been well exhibited as the primary 
HER2 receptor blocker, derived from murine mAb 4D5 (43). A number of 
possibilities have already been established to define the mechanism of actions how 
TmAb works to inhibit the tumor angiogenesis and tumor cell proliferation (figure-
2.3) (44). 
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Figure-2.3: Mechanism of action of TmAb (44) 
 
An open configuration exhibits on the ECD of HER2 receptor which is 
always available for the dimerization with itself (homo-dimerization) and with other 
HER family member receptors (hetero-dimerization). TmAb is able to bind with C-
terminal portion of ECD-IV alike other mAbs (45). Fab region of TmAb is thought to 
bind the membrane surface antigens of target cells while the Fc region of the mAb is 
free to be recognized by the Fc-gamma (Fcγ) receptors of the immune effector cells like 
natural killer (NK) cells. Upon binding, NK cells release cytokines and cytotoxic 
materials to lyse the target cell by stimulating the apoptosis process. This is called 
Ab dependent cell mediated or cellular cytotoxicity (ADCC) which is the 
extracellular mechanism of action of TmAb (46). 
The regulatory proteins of cells control the cell cycle development and 
apoptosis, which can be functionally interrupted due to HER2 overexpression or 
mutation. In HER2 overexpressed condition, cell signaling through both PI3K-
mTOR and STAT-MAPK dependent pathways are subjected to be enhanced. Thus, 
both tumor cell’s proliferation and survival get stimulated by regulating cyclin-
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dependent kinase inhibitor and by inhibiting apoptosis process (47) (48). TmAb 
hinders the dimerization or activation of HER2 which consequences the inhibition of 
cell cycle arrest and the decreased signaling through both PI3K-mTOR and STAT-
MAPK dependent signaling pathways (49) (50) (51) (52) (53) (54).  
Due to proteolytic cleavage, ligand free tyrosine kinase HER2 receptor 
causes the release of ECD and phosphorylated p95 (a truncated membrane bound 
HER2 fragment with Mr~95000). In HER2 overexpressed breast cancers, p95 is 
concomitant with the positive lymph nodal metastasis (55). TmAb blocks both basal 
and activated HER2 ectodomain cleavages, which thereby stop the phosphorylation 
of p95 (56).  
Tumor cells secret some important growth factors such as vascular 
endothelial growth factor (VEGF), transforming growth factor-α to induce 
angiogenesis for their own growth and proliferation. In breast cancer, both HER2 
overexpression and VEGF manifestation are inter-related. Treatment with TmAb 
significantly reduces volume and width of blood vessel which ultimately down 
regulates the HER2 overexpressed tumor growth. Vasculature permeability is also 
decreased with TmAb therapy (57).  
Conventional anticancer therapies are associated with various types of 
drawbacks. Cellular DNA damage is one of the important drawbacks of them. In 
damaged cells, activation of cells’ respond is required to repair damaged DNA, 
process of cell cycle arrest and apoptosis. To repair such damaged gene, HER2 
mediated signal transduction pathways play an important role (58) (59). Blocking of 
this HER2 mediated signal transduction pathways by TmAb can lead the inhibition 
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of repairing conventional anticancer therapy induced DNA damages as well as 
tumor cell growth (60) (61). 
 
2.5.2. PLGA NP 
Nanotechnology is now an advanced field of interest for various applications 
(62). Thus, polymeric NP is a significant output of modern nanotechnology practice. 
Most chemotherapeutical drugs are toxic and hydrophobic in nature which requires 
adequate dilution for slow infusion into the body. To overcome these limitations, 
biocompatible and biodegradable polymeric NPs can be employed as a suitable drug 
carriers (63).  
 
Figure-2.4: Composition of PLGA polymer 
 
PLGA is now a widely studied biodegradable co-polymer under required 
applications for effective anticancer drug delivery. PLGA breaks down into two 
endogenous metabolite monomers (lactic acid and glycolic acid) upon hydrolysis of 
its ester linkage within the body (figure-2.4) (64). The main regulatory agencies like 
US FDA and European Medicine Agency (EMA) approved PLGA for numerous 
drug delivery systems to apply in human because of the biocompatibility, swelling 
behavior, easy preparation techniques, mechanical strength, and limited systemic 
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toxicity (5) (65). PLGA is a hydrophobic molecule in nature, which facilitates the 
easy incorporation of most anticancer drugs (6). Targeted drug delivery with 
enhanced half-life can be achieved by the surface functionalization with different 
purpose based various functional groups (66). Vast surface area of PLGA NPs is an 
attractive feature to control the release kinetics, drug loading capacity and 
administration route, which can regulate the degradation of drug into the body (67). 
To optimize targeted therapeutic delivery, preparation of PLGA NPs can be carried 
out by various available methods such as emulsification solvent evaporation, nano-
precipitation, polymerization, self-assembly, ionic gelation, salting out etc. 
However, the preparation methods are dependent on the necessity of its purpose and 
type of drug to be loaded into the NPs (68) (69) (70).  
 
2.5.3. Docetaxel: A choice of cytotoxic drug for HER2 overexpressed breast 
cancer 
 
Figure-2.5: Chemical structure of Docetaxel (60) 
 
Among all anti-neoplastic classes of drug, the taxans family gained 
substantial consideration as a versatile and clinically useful class of anticancer drugs. 
Being a member of taxans family, Doc is now widely used chemotherapeutic agent 
(figure-2.5) (71). Exclusively in breast cancer, Doc has been comprehensively used 
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for trialed over the past decades due to its prolong half-life (11-19 hours), wide 
volume of distribution, enhanced binding affinity with tissues, less toxicity and some 
advantages over other taxans members. Cellular microtubule networking is 
necessary for interphase as well as mitotic functions, which are interrupted by Doc 
more potentially than other anti-neoplastic drugs (72) (4). Doc leads to the 
stabilization of microtubules, since it can bind with the free tubulin and thus inhibits 
the microtubule depolymerization (73). Despite the successive mechanism, Doc is 
reported with relative side effects such as enhanced neutropenia, fatigue, leucopenia, 
stomatitis, alopecia, edema, and diarrhea (74) (75). In addition, Doc is associated 
with poor water solubility and systemic cytotoxicity mostly due to broad spectrum 
administration (76). Such limitations can be minimized by selective tumor cell 
targeting using nano-carriers such as polymeric NPs, which carry the drug to the 
specific desired cell environment to inhibit infected cell replication. For specific 
binding to receptor of targeted cell surface, functionalization of the nano-carriers is 
an essential prerequisite part, which involves the requirement of selective mAb 
conjugation with or without appropriate spacer. 
 
2.5.4. Cross linking agent to functionalize the NP surface 
The concept behind the surface functionalization of NPs is to deliver the 
cytotoxic agents after binding with uniquely expressed or overexpressed receptors of 
target cells, which allows subsequent penetration and accumulation of therapeutic 
drugs into the cells (77). For successful Ab-NP conjugation, spacer or cross linker 
can act as an important utility bridge (102). However, no perfect progression is 
available to control the desired ligand cross linked with PLGA NPs for required 
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targeting effects. Because, most of the ligand-NP conjugation processes using spacer 
has been demonstrated as a self-assembling processes (78). Conjugation between the 
HER2 specific ligand and PLGA NP can be carried out following several attachment 
approaches. Spacer can be homobifunctional and heterobifunctional which depends 
on its reactive group at the end of the spacer arm. 
 
 
Figure-2.6: Chemical structure of BS3 
 
Homobifunctional spacer, bis-sulfosuccinimidyl suberate (BS3) is reported as 
an effective cross linker between Ab and NPs followed by the formation of amide 
linkage (8). In brief, BS3 is an eight-carbon spacer, which consists of two terminal 
hydrophilic sulfonyl groups at the end of its carboxylic moieties, which are to be 
oriented around the surface of NPs. Amide bond between the carboxylic groups of 
BS3 and the lysine groups of Ab is to be formed upon relieving the terminal sulpho-
NHS group from both terminal ends of the spacer (figure-2.6). The mechanism of 
this crosslinking is a simple one step stable and reproducible attachment process 
without any modification of the spacer and antibody. In addition, using such spacer 
has been found with no steric hindrance in earlier study (8) (79). 
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3. PURPOSE OF PROJECT 
 
 
3.1. Purpose  
The primary purpose of this research is to formulate and characterize an ideal 
Doc loaded PLGA NPs functionalized with the TmAb and to observe its in vitro 
effects in breast cancer cells. Afterwards, in vivo experitments could be done in 
HER2 overexpressed tumor bearing mice. 
  
3.2. Rationale 
The rationale of this research focuses on overcoming the current challenges 
related to conventional chemotherapy for cancer patients. Because most of the 
anticancer drugs after clinical use are associated with some limitations such as poor 
solubility profile, multiple drug resistances, short half-life, and instability. In most 
cases, the exposure of chemotherapeutic agents to the normal healthy cells results in 
severe side effects due to nonspecific broad spectrum administration. Sometimes, 
these drawbacks result in the discontinuation of many potential anticancer drugs in 
the very early stage from the market. To overcome these drawbacks, nanotechnology 
offers many new dimensions in targeted drug delivery systems to improve both 
therapeutic efficacies of these anticancer drugs and tumor imaging by early 
detection. Taking the advantages of nano-drug delivery system to overcome the 
existing limitations of conventional chemotherapy, this experimental design has 
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been considered to develop a perfect NP formulation in respect to targeted drug 
delivery system for HER2 positive breast cancer. 
 
3.3. Hypothesis 
The following hypotheses have been assumed to establish a targeted 
chemotherapy for HER2 overexpressed breast cancer: 
1. Docetaxel can be loaded into the PLGA polymeric NPs successfully followed by 
emulsification solvent evaporation technique. 
2. A humanized monoclonal antibody (Trastuzumab) can be covalently attached 
with the homobifunctional cross linking agent (BS3) embedded on PLGA NP 
surface (figure-3.1). 
3. Presence or absence of HER2 specific ligand on NP surface can differentiate the 
degree of cell uptake of Coumarin-6 (instead of docetaxel) loaded NPs in both 
HER2 overexpressed (SKBR-3) and moderate expressed (MCF-7) breast cancer 
cells. 
4. Compared to unmodified NPs, Trastuzumab modified docetaxel loaded PLGA 
NPs can efficiently inhibit the HER2 receptor expression which will stop further 
proliferation breast cancer cells (SKBR-3 and MCF-7) (figure-3.2). 
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Figure-3.1: Graphical representation of TmAb modifed Doc loaded PLGA NP and the 
covalent attachment mechanism between TmAB and BS3 pre-embedded onto the NP 
surface 
 
Figure-3.2: Graphical representation for the predicted fate of TmAb modifed Doc loaded 
PLGA NP to breast cancer cells 
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3.4. Objectives 
Targeted chemotherapy is aimed to avoid broad spectrum distribution of 
available chemotherapeutic drugs into the whole body. Towards this goal, this study 
has been designed primarily to establish docetaxel loaded modified PLGA NPs 
functionalized with trastuzumab which can be able to target overexpressed HER2 
receptors of breast cancer cells. In this regard, the following primary objectives have 
been considered: 
1. Development of trastuzumab modified docetaxel loaded PLGA NPs. 
2. Physicochemical characterization of trastuzumab modified docetaxel loaded 
PLGA NPs in terms of size, polydispersity index, zeta potential. 
3. Quantification of drug loading and drug entrapment efficiency. 
4. Quantification of trastuzumab attached with the docetaxel loaded pre activated 
PLGA NPs. 
5. Identification of the covalent bond between trastuzumab and BS3 embedded on 
the PLGA NPs. 
6. Assessment of cell uptake by coumarin-6 loaded nano-formulations (instead of 
docetaxel). 
7. Evaluation of HER2 expression of breast cancer cells (SKBR-3 and MCF-7) 
after treating the nano-formulations. 
8. Assessment of cell viability and toxicity after treating the nano-formulations 
with breast cancer cells (SKBR-3 and MCF-7). 
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4. MATERIALS AND METHODS 
 
 
4.1. Materials 
Ester terminated PLGA (inherent viscosity 0.15-0.25 dl/g) were purchased 
from LACTEL, Birmingham polymers (USA). Trastuzumab (Herceptin
®
) was from 
Genentech (a member of the Roche group). Docetaxel was purchased from LC 
Laboratories, USA. Polyvinyl alcohol (PVA), BS3, BCA protein assay kit, 0.25% 
Trypsin-EDTA solution and Fetal Bovine Serum were purchased from Sigma-
Aldrich, USA. SKBR-3 and MCF-7 cell lines were purchased from ATCC, USA. 
Hyclone DMEM/High Glucose medium, Hyclone McCoy’s 5A medium, BCA 
Protein Assay-Reducing Agent Compatible, Bovine Gamma Globulin (BGG) 
Standards from Thermo Fisher Scientific Inc., Canada. Analytical grade solvent; 
ethyl acetate was used. 
 
4.2. Methods 
4.2.1. Preparation of NPs 
Oil in water (O/W) emulsification solvent evaporation technique has been 
applied to prepare Doc loaded ester-terminated PLGA NPs (80). At first, ethyl 
acetate was considered as the organic solvent to prepare the oil phase. A weighed 
amount of drug and 65 mg of PLGA co-polymer were dissolved into 1 ml of solvent 
(ethyl acetate). 2.2 % polyvinyl alcohol (PVA) solution was considered as the 
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aqueous phase. A weighted amount of BS3 was added into PVA solution to prepare 
NPs for covalent attachment (8). Then drug and co-polymer (dissolved in the 
solvent) consisting oil phase was transferred drop-wise to aqueous phase and this 
mixture was then primarily emulsified by using micro tip probe-sonicator. 
Therefore, the primarily emulsified mixture was transferred drop-wise into a beaker 
for 1 hr gentle stirring to remove the organic solvent by evaporation. After removal 
of organic solvent, the NP suspension was subjected for centrifugation to recover 
only Doc loaded NPs. To remove the residual of PVA completely from the 
precipitate, the NPs were washed and re-suspended twice with distilled water 
followed by centrifugation at 4° C (25,000 rpm, 25 mins). Finally, suspended NPs 
were freeze-dried for 48 hrs to obtain dried and fine powder (81). And then the dried 
NPs were stored at -20° C (82). 
 
4.2.2. TmAb conjugation process 
4.2.2.1. Physical adsorption 
A weighted amount of BS3 excluded plain or drug loaded ester ended freeze-
dried PLGA NPs was added into phosphate buffer saline (PBS) in a small vial. Then 
varying amounts of TmAb were added into the small vial for physical adsorption 
and kept for 1 hr continuous stirring in room temperature to reduce the chance of 
any aggregation among the NPs (8) (83). Recovery of surface modified NPs was 
followed by washing and centrifugation at 4° C (18,000 rpm, 15-20 mins) twice (7). 
 
4.2.2.2. Covalent conjugation 
Covalent conjugation method is same as physical adsorption method. Only 
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exception is the presence of BS3 in the NP formulations that act as spacer to form 
covalent amide bond with the antibody. 
 
4.2.3. Size analysis, surface charge and yield of preparation 
To investigate the size, size distribution, poly-dispersity index (PDI), and 
zeta potential (ZP), the NPs were suspended in water. Size and size distribution 
measurement of both modified and unmodified NPs were carried out through 
Malvern Zetasizer (84). The measurement was performed for the NPs before and 
after freeze-drying (85). And mean value and standard deviation (SD) from the data 
were also assessed. The measurements were conducted at 25° C and average of four 
samples was reported. The recovery or yield of the NPs was measured using the 
following equation: 
Yield (%) = 
Weight of obtained NPs
Initial weight of polymer, drug, and other ingredients
 X 100 
 
4.2.4. Drug loading and entrapment efficiency by mass spectrometry 
Mass spectrometer has been used to quantitatively determine the amount of 
Doc present in the samples throughout the study following an extraction procedure, 
previously established in our laboratory (86). Quantitation procedure was performed 
on corresponding Doc and internal standard MRM graphs using Analyst software 
version 1.6. 
 
4.2.4.1. Sample preparation 
A stock solution of Doc (100 µg/ml) in methanol was prepared. Working 
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solution of 3.9, 7.8, 15.6, 31.2, 62.5, 125, 250, 500, 1000, 2000, 4000, 8000, and 
16,000 ng/ml concentrations were prepared by serial dilution of the stock solution in 
methanol. For internal standard, a stock solution of paclitaxel 100 µg/ml in methanol 
was also prepared. 
 
4.2.4.2. Preparation of standards, controls and test samples 
To prepare polymer-free standards (Doc in methanol), 10 µl of internal 
standard along with 1 ml of working solution (3.9-1000 ng/ml) were transferred into 
2 ml tubes and vortexed. Polymer-free controls were prepared as such to obtain 100, 
200, 400, and 800 ng/ml Doc concentrations. To prepare standard samples of NP 
formulations, 10 µl of internal standard along with 1 ml of working solution 125-
16,000 ng/ml for PLGA NPs was transferred into 2 ml tubes and vortexed. The 
solvent was then evaporated and 5 mg plain (drug-free) NPs were added to the tube. 
Concentration set of 1250, 2500, 5000, and 10,000 ng/ml was used to prepare 
quality control samples of PLGA NPs. This is while 625, 1250, 2500, and 5000 
ng/ml concentration set was used to prepare quality control samples of PLGA NPs. 
10 µl of internal standard was added to control samples of PLGA NPs and vortexed. 
The solvent was evaporated and 5 mg plain NPs was added to the tube. To prepare 
test samples, 10 µl of paclitaxel solution was added to 2 ml tubes along with 5 mg of 
drug loaded PLGA NPs. Standard, control, and test samples were extracted twice 
with acetone. 
 
4.2.4.3. Drug extraction 
Doc was extracted from PLGA NPs to prepare the samples for mass 
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spectrometric analysis. In brief, 1 ml acetone was added to 5 mg drug-loaded NPs to 
dissolve both polymer and drug. The mixture was vortexed for 30 secs and subjected 
to bath sonication for 30 mins. Then it was centrifuged for 20 mins at 20,000 rpm. 
The supernatant was separated and preserved. The precipitate was then dissolved in 
acetone and the same procedure was repeated. Obtained supernatants from the first 
and second centrifugation step were mixed and evaporated. 1 ml methanol was 
added to the residue, vortexed for 30 secs and centrifuged for 20 mins at 20,000 rpm. 
Doc was then quantified in supernatant using mass spectrometry method. Finally, 
drug loading and encapsulation efficiency (EE) were calculated using the following 
equation: 
Docetaxel loading (𝑤/𝑤) = 
Amount of loaded Docetaxel (µg)
Amount of polymer (mg)
 
 
Encapsulation efficiency (%) = 
Amount of loaded drug (mg)
Initial amount of drug used (mg)
 X 100 
 
 
4.2.5. Determination of TmAb amount attached on the NPs 
The micro-bicinchoninic acid protein assay kit-reducing agent compatible 
(BCA-RAC) and bovine gamma globulin (BGG) standards were used as per 
protocol to determine the amount of TmAb conjugated with per mg of drug loaded 
NPs (7). The amount of Ab attachment was determined using indirect method from 
the unbound Ab present in the collected supernatant during washing steps. For assay 
procedure, the supernatant of unmodified NPs was used as blank standard. As per 
instruction followed by BCA protein assay kit procedure, 96 wells plate was used to 
quantify the unbound Ab amount. Absorbance of the samples was measured at 562 
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nm in BioTek Microplate Reader using Gen5 data analysis software. By plotting the 
absorbance found from the assay versus concentration of the standard solution 
(bovine gamma globulin), a standard curve was yielded (81). The calculation of the 
Ab attachment and the attachment efficiency were done using the following 
equations: 
Trastuzumab attached (per mg of NPs) (w/w) = 
Amount of TmAb attached (µg)
Amount of NPs (mg)
 
 
 
Attachment efficiency (%) = 
Amount of TmAb per mg of NPs (µg)
Initial amount of TmAb used per mg of NPs (µg)
 X 100 
 
 
4.2.6. Identification of the covalent bond between TmAb and BS3 (embedded 
into NPs) 
4.2.6.1. Fourier Transform Infrared (FTIR) spectroscopy  
Infrared (IR) spectra of NPs were recorded on a Bruker IFS 66v/S Fourier 
Transform Spectrometer (Bruker Optics, Billerica, MA) in the mid-IR range at the 
Canadian Light Source, University of Saskatchewan, Canada. All samples were 
mixed with spectroscopic grade potassium bromide (KBr) and mulled to prepare 
pellets. The spectra were taken for KBr pellets in the range of 4000 – 400 cm-1 in 
absorbance mode. 
 
4.2.6.2. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
For the analysis of structural integrity, TmAb was extracted from the 
modified NPs by adding 0.5 ml ethyl acetate into 5 mg of NPs to be dissolved. 
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Maintaining 1:4 ratio, distilled water was added to the dissolved solution and then 
vortexed at 1400 rpm for 15 mins. Two distinct phases were resulted upon 
centrifugation of the solution at 12000 rpm for 10 mins. 5 ml syringe was used to 
extract the water phase to quantify the concentration of TmAb followed by earlier 
mentioned assay procedure (87) (88). Mini-Protean® TGX™ Gel 7.5% was used to 
run SDS-PAGE under non-reduced and denatured conditions as per the protocol 
from Bio-Rad Laboratories (Canada) Ltd. Exactly, 15 µl of each samples of 1µg/µl 
TmAb concentration was loaded per well. The gel was stained with Coomassie 
Brilliant Blue R-250 staining solution (Bio-Rad, Canada) for 3 hrs and later de-
stained with de-staining solution (Bio-Rad, Canada) for whole night gently at room 
temperature in a shaker. 
 
4.2.7. Cell culture 
SKBR-3 and MCF-7 breast cancer cell lines were considered as the positive 
detection of HER-2 over and moderate expression respectively (89). These cells 
were routinely cultured in the respective medium consisting 10% fatal bovine serum 
(FBS) and 1% penicillin (100 IU/ml)-streptomycin (100 µg/ml) solution followed by 
ATCC guideline. Routine cell culture was carried out in the incubator with a set 
temperature of 37° C in humidified atmosphere containing 5% CO2. The harvesting 
of cells from culture plates was performed using 0.25% trypsin-EDTA solution. 
 
4.2.8. Quantification of Coumarin-6 (Coum-6) in NPs 
To quantify the amount of Coum-6 in NPs, the particles were dissolved in 
methanol and kept overnight in dark. Then the fluorescence intensity was measured 
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at the emission wavelength of 505 nm using a fluorescent spectrophotometer with a 
microplate reader (90). 
 
4.2.9. Cellular uptake 
4.2.9.1. Flow cytometry analysis 
4.2.9.1.1. Cellular uptake without TmAb pre-incubation 
1.5x10
5
 cell cells were plated in each well of 6 wells suspension culture plate 
with culture medium and kept for 24 hrs in the incubator. 0.5 mg of Coum-6 loaded 
both unmodified and modified NPs were incubated with both cell lines for 24 hrs. 
After incubation, cells were washed twice with 2% ice cold FBS containing PBS. 
0.25% trypsin-EDTA solution was used to harvest the adherent cells from the plate. 
After centrifugation, cells were washed with FACS buffer twice prior to be analyzed 
using flow cytometry (91). 
 
4.2.9.1.2. Cellular uptake after TmAb pre-incubation 
To explore the binding efficacy of TmAb to HER2 receptor, the respective 
cell types of varying HER2 expression levels were preincubated with TmAb before 
treating the cells with TmAb modified and unmodified Coum-6 loaded NPs. In brief, 
1.5x10
5
 MCF-7 and SKBR-3 cells were seeded in each 6 well plates and were kept 
in the respective culture mediums for overnight. The next day, cells were treated 
with TmAb (1 µg/µl concentration) for 30-45 mins into the incubator (92). Followed 
by 30-45 mins of pre-incubation, cells were then treated with plain [NP (Coum-6)], 
physically TmAb attached [NP (Coum-6)-TmAb] and covalently attached [NP 
(Coum-6)-BS3-TmAb] Coum-6 loaded NPs at 0.25 mg/ml concentration into the 
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incubator for overnight. After incubation of cells with different NPs, cells were 
harvested following the same procedures as stated above to measure the cell uptakes 
using flow cytometry. 
 
4.2.9..2. Confocal laser scanning microscopy 
In order to visualize the binding and internalization into the cells, confocal 
laser scanning microscopy (CLSM) was employed for both cell types. Briefly, 
coverslips were kept in each well of 6 wells plate prior to plate the cells for NP 
treatments. The condition of cell culture and treatments with different Coum-6 
loaded NPs were the same as stated in the cellular uptake without TmAb pre-
incubation section. In the day of sample preparation, coverslips of adhered cells 
were washed twice with ice-cold PBS and fixed with 4% paraformaldehyde for 25 
mins. After that, the fixed cells were washed twice again with ice-cold PBS and the 
nuclei of the cells were counterstained with gold anti-fade reagent with DAPI (4', 6-
diamidino-2-phenylindole) prior to subject under the confocal microscope. 
 
4.2.10. Measurement of HER2 expression 
4.2.10.1. Flow cytometry analysis 
1.5x10
5
 cells were plated in each well of 6 wells suspension culture plate 
with culture medium and kept for 24 hrs in the incubator. For the treatment of cells, 
same concentration of TmAb attached with NPs was considered as the standard. 
Different NP formulations were incubated with both cell lines for different time 
points. After incubation at different time points, cells were washed twice with 2% 
ice cold FBS containing PBS. 0.25% trypsin-EDTA solution was used to harvest the 
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adherent cells from the plate. After centrifugation, cells were washed with PBS and 
then stained with FITC conjugated anti-HER2 Ab which was purchased from BD 
Bioscience, Canada. After incubation with labeled Ab, ice cold FACS buffer was 
used to wash unbound labeled Ab from the cells twice prior to flow cytometric 
analysis. 
 
4.2.10.2. Western blot analysis 
Protein was isolated from both cell types after NP treatment by lysis with 
sample buffer and then to ensure equal amount of loading on gel, protein 
concentration was assayed using the BCA protein assay kit. For different types of 
NP formulations, HER2 expressions of both cell types were analyzed following 
previously described Western Blot analysis method (89) (93) (94). 
 
4.2.10.3. Fluorescence microscopic analysis 
Glass coverslips were kept in each well of 6 wells plate. 1.5x10
5
 cells were 
plated in each well of 6 wells plate with culture medium and kept for 24 hrs in the 
incubator. For the treatment of cells, a weighted amount of TmAb and drug loaded 
TmAb modified NPs were considered after refreshing cells with new media. After 
48 hrs of incubation, samples were washed with ice-cooled PBS and fixed with ice-
cooled 2% paraformaldehyde for 20 mins. After 2 times washing, cells were treated 
with anti-HER2 FITC Ab at room temperature for 45 mins and washed 2 times again 
to remove unbound labeled Ab from the cells before sampling with DAPI to 
counterstain the nucleus. Fluorescence images were obtained using Olympus 
fluorescence microscope with 40X objective lens. 
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4.2.11. Cell viability and toxicity studies 
The impact of different NPs formulations on HER2 overexpressed (SKBR-3) 
and HER2 moderate expressed (MCF-7) breast cancer cells was evaluated by using 
Annexin V-FITC/Propidium Iodide (PI) staining according to the protocol provided 
by BD biosciences. In details, 1x10
6
 cells were plated in each well of 6 wells plate 
with culture medium and kept for 24 hrs in the incubator. In the next day, media was 
refreshed and treated with the same formulations with same conditions as stated in 
the HER2 expression measurement section for 48 hrs. After the treatment, cells were 
washed twice with cold PBS and then resuspended cells in 1x binding buffer [0.1 M 
Hepes/NaOH (pH 7.4), 1.4 M NaCl, and 25 mM CaCl2]. Then 10µl of cells (1x10
5
) 
suspension was transferred into a 5 ml culture tube. For staining the cells, 5µl 
Annexin V-FITC and 5µl PI were added with gentle shaking and kept for 15 mins 
incubation at room temperature in dark milieu. 400 µl of 1x binding buffer was 
added to each tube before subjecting for the flow cytometry analysis. Untreated 
unstained cells, untreated cells stained with Annexin V-FITC, untreated cells stained 
with PI, and untreated cells stained with both Annexin V-FITC and PI were 
considered as control standards. The basal level of apoptotic and dead cells was 
considered for the untreated cell population stained with Annexin V-FITC and PI. 
Subtraction of the apoptotic or necrotic percentage for untreated cells from that of 
treated cells was considered to be the percentage of cells being induced to undergo 
apoptosis or necrosis due to the treatments. 
 
4.2.12. Statistical analysis 
Data were analyzed by descriptive statistics, calculating the mean and 
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standard deviation (mean ± SD) for continuous variables. The paired student’s t-test 
has been considered to evaluate the differences between modified versus un-
modified NPs. The level of significance is set to p<0.05. 
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5. RESULTS AND DISCUSSIONS 
 
5.1. Size, PDI, and ZP 
Size, PDI, and ZP measurements of the NP formulations are important 
considerations prior to in vitro and in vivo experiments. All the prepared NPs were 
characterized in terms of size, PDI, ZP expressed as mean ± SD. One-way ANOVA 
analysis of variance and Newman-Keuls multiple comparison test were performed to 
demonstrate statistical differences at α level of 0.05 using the software GraphPad 
Prism 5 for Windows. The characterizations were performed considering different 
conditions including before and after freeze-drying, and TmAb attachment with the 
NPs. 
 
5.1.1. Plain NPs (without Doc) 
5.1.1.1. Plain NPs freeze-dried with no cryoprotectant 
Table-5.1 shows the data for all the plain NPs, which did not have any drug 
and freeze-dried with no cryoprotectant.  
Table-5.1: Size, PDI and ZP of plain NPs without drug and freeze-dried with no 
cryoprotectant (n=10) 
NPs 
Before freeze-drying After freeze-drying 
Mean Z-
Ave (nm) 
± SD 
Mean 
PdI 
± SD 
Mean 
ZP 
(mV)  
± SD 
Mean Z-
Ave (nm)  
± SD 
Mean 
PdI 
± SD 
Mean 
ZP 
(mV)  
± SD 
Plain 158.8±5.6 0.20±0.03 -5.4±1.1 344.1±56.1 0.54±0.11 -14.7±3.4 
Plain+BS3 136.7±8.2 0.12±0.02 -5.5±0.7 330.1±71.6 0.46±0.12 -18.5±7.9 
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The mean size of plain NPs without incorporation of drug and BS3 was 
found to be 158.8±5.6 nm, whereas mean size of BS3 containing plain NPs was 
measured to be 136.7±8.2 nm before freeze-drying. This result indicates a slightly 
lower average particle size after BS3 inclusion in the plain NP formulation before 
freeze-drying. Freeze-drying was found to increase the particle size of NPs that was 
confirmed by the high PDI. The ZP values also shifted towards more negative after 
freeze-drying. 
 
5.1.1.2. Plain NPs freeze-dried with cryoprotectant 
Table-5.2 summarizes the data for plain NPs using cryoprotectant (10% 
sucrose). When cryoprotectant was present in the formulation, the mean size of NPs 
before freeze-drying was found to be 148.1±6.8 nm and 132.3±3.9 nm for plain NPs 
and NPs containing BS3, respectively. 
Table-5.2: Size, PDI and ZP of plain NPs without drug and freeze-dried with 10% 
cryoprotectant (n=10) 
NPs 
Before freeze-drying After freeze-drying 
Mean Z-
Ave (nm)  
± SD 
Mean 
PdI 
± SD 
Mean 
ZP (mV)  
± SD 
Mean Z-
Ave (nm)  
± SD 
Mean 
PdI 
± SD 
Mean ZP 
(mV)  
± SD 
Plain+10% Suc 148.1±6.8 
0.13± 
0.03 
-10.6±2.2 242.9±11.4 
0.16± 
0.02 
-10.7±1.7 
Plain+BS3+10% 
Suc 
132.3±3.9 
0.12± 
0.02 
-13.2±4.8 228.6±7.2 
0.17 ± 
0.03 
-4.8±2.3 
 
From table-5.2, it can be concluded that average particle size and PDI values 
of plain NPs were improved having reduced range before and after freeze-drying but 
no significant change was observed for surface charge of the NPs. 
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5.1.1.3. Plain NPs formulations with different amounts of BS3 
Different amounts of BS3 ranging from 1.5 mg to 9 mg were used to prepare 
BS3 containing plain NPs to investigate the covalent binding efficiency of NPs to 
TmAb. Table-5.3 shows the mean particle size, PDI and ZP data for the BS3 
containing NPs freeze-dried with and without cryoprotectant.  
Table-5.3: Size, PDI and ZP of plain NP formulations with different amounts of BS3 (n=3) 
NPs 
Before freeze-drying After freeze-drying 
Mean 
Z-Ave 
(nm)  
± SD 
Mean 
PdI 
± SD 
Mean 
ZP 
(mV)  
± SD 
Mean Z-
Ave (nm)  
± SD 
Mean 
PdI 
± SD 
Mean 
ZP 
(mV)  
± SD 
Plain 158.8±5.6 0.20±0.03 -5.4±1.1 344.1±56.1 0.54±0.11 -14.7±3.4 
Plain+10% Suc 148.1±6.8 0.13±0.03 -10.6±2.2 242.9±11.4 0.16±0.02 -10.7±1.7 
Plain+BS3 (1.5mg) 136.7±8.2 0.12±0.02 -5.5±0.7 330.1±71.6 0.46±0.12 -18.5±7.9 
Plain+BS3 
(1.5mg)+10% Suc 
132.3±3.9 0.12±0.02 -13.2±4.8 228.6±7.2 0.17±0.03 -4.8±2.3 
Plain+BS3 (3mg) 131.1±3.9 0.17±0.02 -14.6±0.5 375.8±106.5 0.51±0.23 -13.3±9.6 
Plain+BS3 
(3mg)+10% Suc 
139.8±6.1 0.14±0.01 -10.4±0.3 227.5±47.9 0.19±0.05 -15.6±2.5 
Plain+BS3 (6mg) 129.8±4.1 0.13±0.01 -19.6±0.5 375.7±162.1 0.26±0.19 -14.8±5.5 
Plain+BS3 
(6mg)+10% Suc 
142±4.8 0.12±0.01 -18.1±0.9 274.1±18.3 0.30±0.14 -9.9±1.7 
Plain+BS3 (9mg) 139.5±3.6 0.13±0.01 -18.5±0.5 311.8±144.8 0.36±0.12 -14.1±2.4 
Plain+BS3 
(9mg)+10% Suc 
131.6±2.2 0.11±0.01 -14.4±0.6 278.8±56.1 0.24±0.14 -12.3±0.7 
 
Table-5.3 shows that using cryoprotectant in the formulation improved the 
particle size and PDI after freeze-drying although no statistical correlation could be 
made. Surface charge of the BS3 containing plain formulations with 10% 
cryoprotectant were observed to be less than -20mV. However, ZP values showed a 
more negative trend by increasing the amount of BS3 in NPs. 
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5.1.2. Doc loaded NP formulations 
5.1.2.1. Effect of different Doc concentrations in NP formulations with no BS3 
Doc concentrations of 0.75 mg/ml to 3 mg/ml were initially used to prepare 
the drug loaded NPs using cryoprotectant as summarized in table-5.4. Particle sizes 
of Doc loaded NP formulations without BS3 were in range from 133.6±3.6 to 
141.1±3.8 before freez-drying and from 202.3±3.6 to 235.6±15.2 after freeze-drying. 
The ZP values of these formulations varied from -13.7±3.8 to -17.6±4.4 befrore 
freeze-drying and -5.4±1.1 to -7.8±1.9 after freeze-drying. The obtained PDI values 
were below 0.15 and 0.25 before and after freeze-drying, respectively. 
Table-5.4: Size, PDI and ZP of Doc (different concentrations) loaded NP formulations 
without BS3, freeze-dried with cryoprotectant (n=3) 
NPs 
Before freeze-drying After freeze-drying 
Mean 
Z-Ave 
(nm)  
± SD 
Mean 
PdI 
± SD 
Mean 
ZP 
(mV)  
± SD 
Mean Z-
Ave (nm)  
± SD 
Mean 
PdI 
± SD 
Mean 
ZP 
(mV)  
± SD 
Plain+10% Suc 148.1±6.8 0.13±0.03 -10.6±2.3 242.9±11.4 0.16±0.02 -10.7±1.7 
0.75 mg/ml 
Doc+10% Suc 
141.1±3.8 0.12±0.03 -13.7±3.8 235.6±15.2 0.23±0.02 -5.4±1.1 
1.5 mg/ml 
Doc+10% Suc 
135.4±5.1 0.14±0.03 -14.2±1.3 302.1±8.5 0.19±0.01 -6.8±4.9 
3 mg/ml 
Doc+10% Suc 
133.6±3.6 0.14±0.02 -17.6±4.4 202.3±3.6 0.21±0.01 -7.8±1.9 
 
A lower trend for average size range was found while increasing Doc 
concentration in drug loaded NP formulations when compared with that of the plain 
NPs. In BS3 free Doc loaded NP formulations, the surface charges were moved 
towards more negative with the increase of drug concentration used to prepare the 
NPs. After freeze-drying the drug-loaded formulations with cryoprotectant, the 
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surface charges shifted towards less negative compared to before freeze-drying. 
However, no significant differences were found after statistical analysis. 
 
5.1.2.2. Effect of different Doc concentrations in NP formulations with BS3 
Table-5.5 summarizes the data for BS3 included NP formulations containing 
Doc with various concentrations from 0.75 mg/ml to 3 mg/ml. The mean size of BS3 
containing drug-loaded formulation was found in a range from 131.0±5.7 nm to 
144.1±3.8 nm in the presence of 10% cryoprotectant, before freeze-drying. The size 
range after freeze-drying was found to be from 279.5±6.9 nm to 309.4±7.6 nm. The 
ZP values of these formulations varied from -12.9±1.9 to -17.1±2.5 befrore freeze-
drying and -4.6±0.5 to -8.1±3.6 after freeze-drying. In fact, PDI values were found 
to be similar for all cryoprotectant-containing formulations before and after freeze-
drying. 
Table-5.5: Size, PDI and ZP of Doc (different concentrations) loaded BS3 included NP 
formulations freeze-dried with no cryoprotectant (n=3) 
NPs 
Before Freeze Drying After Freeze Drying 
Mean Z-
Ave (nm)  
± SD 
Mean 
PdI 
± SD 
Mean 
ZP 
(mV)  
± SD 
Mean Z-
Ave (nm)  
± SD 
Mean 
PdI 
± SD 
Mean 
ZP 
(mV)  
± SD 
Plain+BS3+10% 
Suc 
132.3±3.9 0.12±0.02 -13.2±6.2 228.6±7.2 0.17±0.03 -4.8±2.3 
0.75 mg/ml 
Doc+BS3+10% 
Suc 
144.1±3.8 0.10±0.03 -12.9±1.9 279.5±6.9 0.19±0.02 -4.6±0.5 
1.5 mg/ml 
Doc+BS3+10% 
Suc 
135.0±5.5 0.14±0.04 -18.0±3.1 231.9±18.9 0.27±0.05 -7.9±3.4 
3 mg/ml 
Doc+BS3+10% 
Suc 
131.0±5.7 0.13±0.04 -17.1±2.5 309.4±7.6 0.19±0.02 -8.1±3.6 
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Similar trend of decreasing size of Doc loaded NPs was also observed with 
increasing the initial concentration of drug used in the BS3 included formulations. 
PDI values for the BS3 containing formulations and NPs without BS3 followed the 
similar trend. It indicates that BS3 inclusion as cross linking agent in the 
formulations may not affect the size distribution profile of this NP formulation 
strategy. In addition, surface charges of the BS3 containing drug loaded NP 
formulations were observed to be slightly more negative compared to the 
formulations with no BS3 before freeze-drying. 
 
5.1.3. Effect of TmAb attachment to the NP formulations  
Table-5.6 represents the physicochemical characteristics of TmAb modified 
NPs considering both methods of TmAb attachment: physical adsorption and 
covalent conjugation compared to the plain NPs. All the formulations in table-5.6 
were freeze-dried with 10% cryoprotectant. Particle size ranges of TmAb modified 
NP formulations were from 313.4±12.8 to 374.3±57.3. PDI values of the NP 
formulations were found to be below 0.5 after TmAb conjugation. Surface charge of 
TmAb modified NPs was in range between + 3.2±0.5 mV and + 4.3±0.3 mV. 
After TmAb conjugation with NPs, a significant increase in the average 
hydrodynamic diameter (300 - 450 nm) was observed. No significant change in 
terms of PDI values was shown after TmAb functionalization. Most importantly, a 
significant change in surface charge was observed for the NPs after TmAb 
attachment which shifted towards positive to nearly neutral. This indicates the 
presence of positively charged Ab on the NP surface. 
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Table-5.6: Size, PDI and ZP of TmAb modified Doc (different concentrations) loaded 
BS3 (1.5 mg) included NP formulations compared to BS3 excluded plain NPs, TmAb 
modified BS3 excluded plain NPs (n=10). All the NP formulations were freeze-dried with 
10% cryoprotectant 
Formulations 
Before TmAb Conjugation After TmAb Conjugation 
Mean 
Z-Ave 
(d.nm)
± SD 
Mean 
PdI ± 
SD 
Mean 
ZP 
(mV) ± 
SD
 
(mV) 
Mean Z-Ave 
(d.nm)± SD 
Mean 
PdI ± 
SD 
Mean 
ZP 
(mV) ± 
SD 
(mV) 
NP 148.1±6.9 0.13±0.03 -10.6±2.2 262.80±63.18
*a
 0.24±0.10
 a
 -4.7±0.3
* a
 
TmAb-NP 148.1±6.9 0.13±0.03 -10.6±2.2 362.30±70.73
*
 0.40±0.04 3.5±0.5
*
 
TmAb-BS3-NP 145.1±4.8 0.12±0.05 -11.5±1.4 374.25±57.29
*
 0.33±0.15 4.3±0.3
*
 
TmAb-BS3-
Doc(0.75)-NP 
131.0±5.7 0.13±0.04 -17.1±2.5 368.40±39.36
*
 0.38±0.24 4.1±0.6
*
 
TmAb-BS3-
Doc(1.5)-NP 
135.0±5.5 0.14±0.04 -18.0±3.1 313.40±12.76
*
 0.25±0.06 3.2±0.5
*
 
TmAb-BS3-
Doc(3)-NP 
144.1±3.9 0.10±0.03 -12.9±1.9 317.40±24.76
*
 0.44±0.12 4.1±0.4
*
 
 
Formulation details 
NP : Plain PLGA NP without Doc 
TmAb-NP : TmAb attached plain NP with no BS3 (physical 
adsorption) 
TmAb-BS3-NP : TmAb covalently attached with BS3 of plain NP 
TmAb-BS3-Doc(0.75)-NP : Doc (0.75 mg/ml; initial concentration) loaded TmAb 
attached BS3 containing NP (covalent attachment) 
TmAb-BS3-Doc(1.5)-NP : Doc (0.1.5 mg/ml; initial concentration) loaded TmAb 
attached BS3 containing NP (covalent attachment) 
TmAb-BS3-Doc(3)-NP : Doc (3 mg/ml; initial concentration) loaded TmAb 
attached BS3 containing NP (covalent attachment) 
 
* 
Statistically different from the nano-formulations before TmAb attachment 
a 
Without TmAb attachment (for control) but maintained in same condition alike 
TmAb  attachment 
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5.2. Drug loading and entrapment efficiency 
Doc was used as a model drug and loaded into the PLGA NPs at various 
initial concentrations ranging from 0.75mg/ml to 3 mg/ml. In addition to the 
previously mentioned physicochemical characterization, the Doc loaded 
formulations were also assessed for their degree of drug loading and drug 
entrapment efficiency using mass spectrometry analysis.  
 
5.2.1. Doc loaded NP formulations with no BS3 
Doc concentrations of 0.75 mg/ml to 3 mg/ml were used to incorporate into 
the NPs, which were freeze-dried with 10% cryoprotectant. Table-5.7 summarizes 
the EE (%), drug loading (%), µg of drug/mg NPs, and µg of drug/mg NPs 
(theoretical) for all the NP formulations with no BS3 incorporation.  
Table-5.7: Drug loading, EE (%) of the Doc (different concentrations) loaded BS3 
excluded NP formulations freeze-dried with 10% cryoprotectant (n=3) 
NPs 
Drug Loading  
(µg/mg of NPs) 
EE (%) Yield (%) 
0.75 mg/ml Doc+10% Suc 1.89±0.36 16.40±3.14 51.67±2.30 
1.5 mg/ml Doc+10% Suc 4.02±0.02 17.42±0.09 46.01±8.66 
3 mg/ml Doc+10% Suc 7.01±1.11 15.17±2.41 57.67±10.1 
 
EE was measured to be in a range from 15.17±2.41 % to 17.42±0.09 % and 
the recovery of NPs after freeze-drying (yield) ranging from 46.01±8.66 % to 
57.67±10.10 %. Amount of drug per mg of NPs (loading) was calculated to be in a 
range from 1.89±0.36 µg to 7.01±1.11 µg. Among the drug loaded formulations 
without BS3, drug concentration of 3 mg/ml demonstrated the lowest EE and 1.5 
mg/ml showed the highest EE. Loading was calculated to be the highest for 3 mg/ml 
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and lowest for 0.75 mg/ml drug concentration. The yield of NP preparation was 
assessed to be below 50% for drug concentration of 1.5 mg/ml, however, the 
differences were not statistically significant. 
 
5.2.2. Doc loaded NP formulations with BS3 
To evaluate the effect of BS3 inclusion in drug loading, Doc concentrations 
of 0.75 mg/ml to 3 mg/ml were used to load into the BS3 containing NP 
formulations using cryoprotectant. Table-5.8 shows the EE (%), drug loading (%), 
µg of drug/mg NPs, and µg of drug/mg NPs (theoretical) for all the NP formulations 
with BS3. 
Table-5.8: Drug loading, EE (%) of the Doc (different concentrations) loaded BS3 
included NP formulations freeze-dried with 10% cryoprotectant (n=3) 
NPs 
Drug Loading  
(µg/mg of NPs) 
EE (%) Yield (%) 
0.75 mg/ml Doc+BS3+10% Suc 3.11±0.15 26.98±1.30 42.33±3.21 
1.5 mg/ml Doc+BS3+10% Suc 3.31±0.52 15.64±0.55 51.67±8.08 
3 mg/ml Doc+BS3+10% Suc 7.13±0.89 15.44±1.94 52.33±10.69 
 
Table-5.8 shows that EE was found in a range from 15.44 ± 1.94 % to 26.98 
± 1.30 % with the yield of NPs after freeze-drying varried from 42.33±3.21 % to 
52.33±10.69 %, respectively. Around 3.11±0.15 µg/mg to 7.13±0.89 µg/mg of the 
drug was loaded into NPs depending on the initial concentration of the drug used. 
Lowest EE was reported with the NP formulation with drug concentration of 3 
mg/ml and hightest EE was found with the drug concentration of 0.75 mg/ml. 
However, higher loading was found for for the NP formulations with 3 mg/ml drug 
concentration and lowest was for 0.75 mg/ml drug concentration. The concentration 
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of 0.75 mg/ml after freeze-drying the NPs showed the lowest yield of NP 
preparation, which was less than 50 %.  
Figure-5.1 and figure-5.2 represent the the statistical analysis after one-way 
ANOVA analysis of variances based on the results of drug loading per mg of NPs 
and drug EE in table-5.7 and table-5.8. NP formulation of 0.75 mg/ml drug 
concentration was found with statistically moderate significant difference between 
same drug concentration groups (with and without BS3). But, no statistically 
significant differences were found between the other drug loaded NP formulations of 
similar drug concentration groups. Similar trend was also observed for the drug EE 
of all Doc loades NP formulations.  
 
 
Figure-5.1: Comparative drug loading of Doc loaded NP formulations with different drug 
concentrations (n=3). 10% cryoprotectant was used in all the formulations. The statistical 
significances between the groups were represented by indicating the encompassed lines with 
the number of (*) sign.  The level of significance was set to p < 0.05 (one-way ANOVA 
followed by Tukey's multiple comparison test method). Each bar represents the mean % ± 
SD (n=4) 
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Figure-5.2: Comparative drug loading efficiency of NP formulations with different drug 
concentrations (n=3). 10% cryoprotectant was used in all the formulations. The statistical 
significances between the groups were represented by indicating the encompassed lines with 
the number of (*) sign.  The level of significance was set to p < 0.05 (one-way ANOVA 
followed by Tukey's multiple comparison test method). Each bar represents the mean % ± 
SD (n=4) 
 
Compare to theoretical amount of drug to be loaded per mg of NPs, 
practically loaded amount of drug into the NPs was found very low. The loaded 
amount of drug into the NPs and EE were found correlated where the increase in 
initial drug concentration resulted with reduced EE and vice versa. 
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5.3. TmAb quantification 
Both physically adsorption (without BS3) and covalent attachment (with 
BS3) methods were employed to conjugate TmAb with the NPs. The desired NP 
formulations for TmAb modification were evaluated for their level of TmAb 
attachment. 
 
5.3.1. Effect of different amounts of BS3 in the plain NP formulations with 
constant amount of Ab 
To measure the efficiency of NPs for TmAb binding, different BS3 amounts 
were incorporated to prepare the plain NPs. A constant amount of TmAb was used 
for all the formulations. Table-5.9 shows the comparative TmAb attachment per mg 
of NPs, when Tm Ab is attached by physical absorption (TmAb-NP) or covalent 
conjugation (TmAb-BS3-NP). No significant increase in TmAb attachment was 
observed with increasing BS3 amounts in the formulations.  
Table-5.9: Comparative amounts of TmAb attachment and binding efficiency after 
incubation of same amount of TmAb to the different amounts of BS3 in the NP 
formulations freeze-dried with 10% cryoprotectant (n=10) 
NP formulations 
TmAb attached/mg of 
NPs (µg) ±SD 
TmAb attachment efficiency 
(%)
*
±SD 
TmAb-NP 5.93±0.64 47.41±5.14 
TmAb-BS3(1.5)-NP 7.19±0.80 57.47±3.21 
TmAb-BS3(3)-NP 4.86±0.71 38.87±5.67 
TmAb-BS3(6)-NP 1.71±0.38 13.67±3.02 
TmAb-BS3(9)-NP 3.49±0.77 27.94±6.12 
∗ TmAb attachment efficiency (%) =  (
Ab attached per mg of NP
Initial amount of Ab used
) X 100
 
* Fixed amount of TmAb treated per mg of NPs = 12.5µg  
* TmAb is physically absorbed to the NPs (TmAb-NP) 
* Various amounts of BS3 used to prepare NPs ranges from 1.5 to 9mg (TmAb-BS3-NP) 
* Condition for the TmAb attachment: 4
ᵒ
C  
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Higher TmAb attachment efficiency was found when a lowest amount of 
BS3 was used in the formulation although comparible attachment efficiency was 
observed between adsorption and covalent conjugation. 
 
5.3.2. Effect of different amounts of TmAb and BS3 on the plain NP 
formulations 
In order to optimize the TmAb modified NPs, different TmAb amounts were 
considered to incubate with the different amounts of BS3 containing plain NPs. 
Table-5.10 shows the comparative TmAb attachment amount and attachment 
efficiency per mg of NPs. 
Table-5.10: Comparative amounts of TmAb attachment and binding efficiency after 
incubation of different amounts of TmAb to the different amounts of BS3 in the NP 
formulations freeze-dried with 10% cryoprotectant (n=10) 
NP formulations 
TmAb attached/mg of 
NPs (µg) ±SD 
TmAb attachment 
efficiency (%)
*
±SD 
TmAb(125)-NP 2.67±0.31 42.94±5.01 
TmAb(125)-BS3(1.5)-NP 3.07±0.23 47.94±3.72 
TmAb(250)-BS3(3)-NP 5.82±0.29 46.57±2.32 
TmAb(500)-BS3(6)-NP 10.93±0.62 43.71±2.48 
TmAb(500)-BS3(9)-NP 11.46±0.65 45.85±2.58 
∗ TmAb attachment efficiency (%) =  (
Ab attached per mg of NP
Initial amount of Ab used
) X 100 
* Various amount of TmAb treated per mg of NPs ranges from 125µg to 500ug 
* Various amounts of BS3 used to prepare NPs ranges from 1.5mg to 9mg 
* Condition for the Ab attachment 4
ᵒ
C 
 
5.3.3. Effect of various conjugation conditions for attaching TmAb to the Doc-
loaded NPs 
In order to obtain an optimum TmAb attachment efficiency, two types of 
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conjugation conditions were also considered such as 4
ᵒ
C and room temperature. 
Table-5.11 shows the comparative TmAb attachment amount and efficiency to the 
NPs.  
Table-5.11: Comparative amounts of TmAb attachment and binding efficiency after 
incubation of fixed amount of TmAb to the fixed amount of BS3 in the Doc loaded NP 
formulations freeze-dried with 10% cryoprotectant (n=10) 
NP formulations 
TmAb attached per mg 
of NP (µg) ±SD 
TmAb attachment 
efficiency (%)
*
±SD 
At 4
ᵒ
C 
At room 
temperature 
At 4
ᵒ
C 
At room 
temperature 
TmAb-NP 6.32±1.34 14.09±1.46 29.50±6.26 46.95±4.88 
TmAb-(1.5)BS3-NP 6.66±1.12 19.12±1.14 31.06±5.21 63.73±3.79 
TmAb-(1.5)BS3-Doc(0.75)-NP 4.16±1.18 11.02±1.1 19.39±5.51 36.73±5.70 
TmAb-(1.5)BS3-Doc(1.5)-NP 3.39±1.22 8.42±1.95 15.83±5.70 28.06±6.51 
TmAb-(1.5)BS3-Doc(3)-NP 3.77±1.20 12.05±1.39 17.61±5.62 40.17±4.63 
∗ TmAb attachment efficiency (%) =  (
Ab attached per mg of NP
Initial amount of Ab used
) X 100 
* Amount of TmAb treated per mg of NPs = 30µg 
* Amount of BS3 used to prepare NPs = 1.5 mg 
 
Although covalent method showed higher attachment efficiency with drug 
free NPs than adsorption method, however it was not equially potential to attach in 
case of drug loaded NPs in both incubation conditions. However, the percentage of 
TmAb attachment efficiency was found higher at room temperature incubation 
condition. Considering room temperature as a standard condition to attach TmAb 
with all NP formulations, no significant difference was observed after assaying 
TmAb attachment levels. 
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5.4. Identification of the covalent bond between TmAb and BS3 (embedded into 
NPs) 
After attaching TmAb with NPs covalently, it is important to confirm the 
structural integrity of targeting ligand as well as the chemical conjugation. This is an 
essential factor in order to get maximum targeting efficiency. To confirm the 
covalent bond and structural integrity of TmAb modified NPs, two experiments were 
designed such as FTIR spectroscopy and SDS-PAGE. 
 
5.4.1. Identification of covalent bond with FTIR  
A marked peak at the wavelength of 1750 cm
-1
 elicits the presence of a 
carbonyl bond (C=O stretching vibration) which represents the characteristic of 
PLGA (95). Ideally, at the wavelength of near 1640 cm
-1
, an amide bond (C=N 
stretching vibration) can be identified for the presence of the covalent conjugation 
between PLGA NPs and Ab. According to figure-5.3(A), a clear peak spectra at the 
wavelength of 1650 cm
-1
 represents the presence of covalent amide bond for the 
TmAb modified PLGA NP, which corresponds to another C=O stretching bond on 
both components. However, this corresponding stretching bond does not allow to 
draw a concrete conclusion for the covalent conjugation of the NPs (96). In addition, 
the presence of N-H stretching at the wavelength of 3400 cm
-1
 shows comparatively 
higher intensity for the modified NPs than the plain and unmodified NPs. This 
stretched peak spectrum can be considered to differentiate TmAb modified NPs 
from the unmodified one. Figure-5.3(B) represents the secondary derivative for the 
spectrums in figure-5.3(A) to visualize the peak for claimed amide bond (black 
spectra) more closely which was different from other two spectrums. 
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Figure-5.3: Primary and secondary FTIR derivative spectra of (a) 0.15 Ester terminated 
PLGA NPs without BS3 (green), (b) BS3 containing 0.15 Ester terminated PLGA NPs 
(blue) and (c) BS3 containing 0.15 Ester terminated TmAb modified PLGA NPs (red). Data 
is represented in absorbance units versus wavelength (cm
-1
) 
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5.4.2. Identification of covalent bond with SDS-PAGE 
To confirm the covalent conjugation between TmAb and BS3 linked NPs, 
SDS-PAGE study was also designed. As a protein, TmAb may turn into inactive 
state during conjugation with pre-activated NPs due to agglomeration or 
denaturation. To analyze the structural integrity and stability of TmAb, SDS-PAGE 
experiment was carried out after proper extraction from the functionalized NPs. 
 
Figure-5.4: SDS-PAGE for covalent bond between TmAb and BS3 linked NPs: Lane 1 is 
for the molecular marker (Color Plus Prestained Protein Ladder); Lanes 2 to 4 are for native 
TmAb, BS3-TmAb reaction, and extracted TmAb from NPs respectively 
 
Figure-5.4 shows the SDS-PAGE analysis for native TmAb, reaction 
between and TmAb, and extracted TmAb under non-reduced and denatured 
condition as the molecular weight of the mAb is quite high (148 kDa). From the 
figure-5.4, it can be concluded that TmAb remains similar after conjugated with NPs 
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(lane-2 and lane-4). To confirm the covalent bond between BS3 and TmAb, lane-3 
shows two separate bands. One band of those reflects the same as native TmAb 
confirming the unreacted TmAb with BS3 in presence of phosphate buffer saline 
(PBS) and the other band (top, lane-3) is above 230 kDa since both arms of homo-
bi-functional cross-linker successfully reacted with TmAb to increase the molecular 
weight. Thus the confirmation of covalent reaction between mAb and cross-linker 
validates the feasibility of formulating targeted chemotherapeutic drug delivery 
system for HER2 overexpressed breast cancer. 
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5.5. Quantification of Coum-6 in NPs 
To quantify the amount of Coum-6 in plain NP formulations, the dye loaded 
NPs were dissolved in methanol and kept overnight in dark place. Then the 
fluorescence intensity was measured at the emission wavelength of 505 nm using a 
fluorescent spectrophotometer with a micro-plate reader.  
 
5.5.1. Standard curve for Coum-6 
A concentration range from 1μg/ml to 100μg/ml was used to prepare the 
standard curve of Coum-6 in an organic solvent, methanol. A micro-plate reader 
containing fluorescence spectrophotometer (Biotek’s Synergy Gen 5) was used to 
measure the fluorescence intensity of the samples. The excitation and emission 
wavelength were 443 nm and 505 nm, respectively. Figure-5.5 shows the standard 
curve of Coum-6 in methanol. Table-5.12 shows the loading and EE of Coum-6 
using the respective standard curve. 
 
Figure-5.5: Standard curve of Coum-6 
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5.5.2. Coum-6 loading and EE into the plain NP formulations 
 
To simulate the internalization efficiency of drug loaded targeted NPs, 
Coum-6 loaded targeted NPs were considered. Coum-6 loading per mg of NPs was 
found in a range from 19.21±1.05 µg/mg to 22.13±1.74 µg/mg with EE range from 
75.35±1.37% to 83.23±1.89%.  Similar loading tendency was observed in Doc 
loaded NPs. However, the loading and EE of Coum-6 into the PLGA NPs were 
found comparatively higher than the drug loaded NP formulations. 
 
 
 
 
 
 
 
 
 
 
 
Table-5.12: Coum-6 loading and EE for different formulations 
NP formulations 
Coum-6 loading 
(g/mg)±SD 
EE of Coum-6 (%)±SD 
NP (Coum-6) 19.21±1.05 83.23±1.89 
TmAb-NP (Coum-6) 20.23±1.78 81.13±2.66 
TmAb-BS3-NP (Coum-6) 22.13±1.74 75.35±1.37 
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5.6. Uptake study 
Cell uptake of NPs was evaluated in two cell lines: MCF-7 (HER2 moderate 
expressing) and SKBR-3 (HER2 overexpressing). Flow cytometry experiments and 
CLSM were conducted to observe the uptake effects. In addition, dot plots and 
histograms were represented to show the difference in NPs uptake for non-targeted 
and targeted Coum-6 loaded plain NPs. 
 
5.6.1. Uptake study by flow cytometry 
5.6.1.1. Cellular uptake without pre-incubation with TmAb 
5.6.1.1.1. Coum-6 loaded NPs uptake in MCF-7 cells 
Uptake of NPs by MCF-7 cells was conducted utilizing Coum-6 loaded NPs. 
The detector was selected based on the absorption/emission wavelength of Coum-6 
dye. The experiments were repeated four times using the same setting with a 
minimal adjustment. Figure-5.6 shows the dot plots and histograms for the untreated 
MCF-7 cells and treated MCF-7 cells with Coum-6 loaded plain NPs, TmAb 
modified NPs and BS3 containing TmAb modified NPs. Only 1.5% gated 
population was accounted to have fluorescence in the untreated cell group. A gate 
was used to accumulate the signal of fluorescence from 10,000 cell population. This 
number was selected based on flow cytometry experiment done in our previous 
studies and other papers. A shift in fluorescence is evident from the histograms.  
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Untreated MCF-7 cells 
  
MCF-7 cells treated with Coum-6 loaded plain NPs 
  
MCF-7 cells treated with Coum-6 loaded TmAb modified NPs 
  
MCF-7 cells treated with Coum-6 loaded TmAb modified NPs with BS3 
 
 
Figure-5.6: Dot plots and histograms for untreated MCF-7 cells and treated MCF-7 cells 
with Coum-6 loaded loaded plain NPs, TmAb modified NPs and BS3 containing TmAb 
modified NPs (n=4) 
% gated/+ve cells: 1.55/22.26 
% gated/+ve cells: 100/1209.5 
% gated/+ve cells: 100/1709.7 
% gated/+ve cells: 100/2000.8 
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The difference between untreated and treated MCF-7 cells was more 
prominent, when the graphs obtained from the histograms were overlapped in the 
figure-5.7. A comparative difference in uptake can be visualized from the diagram.  
 
Figure-5.7: Overlayed histogram for untreated MCF-7 cells and the MCF-7 cells treated 
with Coum-6 loaded unmodified plain NPs, TmAb modified NPs, BS3-TmAb modified NPs 
(n=4) 
 
For TmAb modified Coum-6 loaded NPs, significant shifts in fluorescence 
were found which is comparatively higher than that of plain Coum-6 loaded NP 
formulations. Also, covalently attached TmAb showed better uptake by the MCF-7 
cells as indicated in figure-5.7 (redline histogram). 
 Untreated Cells FL1-H 
 NP (Coum-6)               FL1-H 
 TmAb-NP (Coum-6) FL1-H 
 TmAb-BS3-NP (Coum-6) FL1-H 
Key Name Parameter 
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Figure-5.8: Bar diagram indicating the fold increase of MFI for untreated MCF-7 cells and 
the MCF-7 cells treated with Coum-6 loaded unmodified plain NPs, TmAb modified NPs, 
BS3-TmAb modified NPs. Fold increase was calculated considering MFI of untreated cells 
as control. The statistical significances between the groups were represented by indicating 
the encompassed lines with the number of (*) sign.  The level of significance was set to p < 
0.05 (one-way ANOVA followed by Tukey's multiple comparison test method). Each bar 
represents the mean % ± SD (n=4) 
 
The fold increase in mean fluorescence intensity (MFI) is shown in figure-
5.8. The difference in MFI indicates that Coum-6 loaded NPs were taken by cells. 
Figure-5.8 represents that the plain NPs showed 39.29±12.7 fold increase in uptake 
when compared with untreated cells. When TmAb was present in the formulation, 
the uptake increased 62.49±17.4 and 79.01±15.7 folds for TmAb-NPs and TmAb-
BS3-NPs, respectively. 
 
5.6.1.1.2. Coum-6 loaded NPs uptake in SKBR-3 cells 
Figure-5.9 shows the dot plots and histograms for the untreated SKBR-3 cells 
and treated SKBR-3 cells with Coum-6 loaded plain NPs, TmAb modified NPs and 
BS3 containing TmAb modified NPs, respectively.  
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Untreated SKBR-3 cells 
 
 
SKBR-3 cells treated with Coum-6 loaded plain NPs 
 
 
SKBR-3 cells treated with Coum-6 loaded TmAb modified NPs 
  
SKBR-3 cells treated with Coum-6 loaded TmAb modified NPs with BS3 
  
 
Figure-5.9: Dot plots and histograms for untreated SKBR-3 cells and treated SKBR-3 cells 
with Coum-6 loaded loaded plain NPs, TmAb modified NPs and BS3 containing TmAb 
modified NPs (n=4) 
 
% gated/+ve cells: 3.5/23.4 
% gated/+ve cells: 100/1117.9 
% gated/+ve cells: 100/1512.6 
% gated/+ve cells: 100/2093.4 
 58 
Following the treatment of SKBR-3 cells with Coum-6 loaded different NP 
formulations, a shift in the fluorescence was observed. Untreated cells showed an 
auto-fluorescence with the MFI of 2.34, which was accounted as the background 
(figure-5.9). An MFI value above background was considered the fluorescence. The 
uptake of plain and modified NPs showed significant difference in fluorescence 
intensity. Shifts in the fluorescence with TmAb modified NPs were significantly 
notable after treating with SKBR-3 cells. The uptake of covalently attached TmAb 
modifie Coum-6 loaded NPs by SKBR-3 cells was prominent compared to 
unmodified and physically TmAb attached NPs. 
Overlaying the histograms as shown in figure-5.10 further clarifies the 
justification of formulating targeted NPs as opposed to non-targeted. Similar trend 
for the shifts in fluorescence was observed as found with the treatment of NPs in of 
MCF-7 cells. However, the MFI found with SKBR-3 cells was comparatively higher 
in comparison to the MFI observed for MCF-7 cells. 
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Figure-5.10: Overlayed histogram for untreated SKBR-3 cells and the SKBR-3 cells treated 
with Coum-6 loaded unmodified plain NPs, TmAb modified NPs, BS3-TmAb modified NPs 
(n=4) 
 
Figure-5.11 shows the relative fold increase in MFI for the untreated SKBR-
3 cells, Coum-6 containing plain NPs, TmAb modified NPs, BS3-TmAb modified 
NP treatment groups. The TmAb modified formulations showed higher fold increase 
in MFI compared to the plain NPs. The fold increase in MFI for plain NPs were 
47.77±14.01. Whereas, the fold increase in MFI for the TmAb modified NPs, BS3-
TmAb modified NPs were 64.64±20.21 and 89.47±34.4 times, respectively. 
 
 
 Untreated Cells FL1-H 
 NP (Coum-6)         FL1-H 
 TmAb-NP (Coum-6) FL1-H 
 TmAb-BS3-NP (Coum-6) FL1-H 
Key Name Parameter 
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Figure-5.11: Bar diagram indicating the fold increase of MFI for untreated SKBR-3 cells 
and the SKBR-3 cells treated with Coum-6 containing plain NPs, TmAb modified NPs, 
BS3-TmAb modified NPs. Fold increase was calculated considering MFI of untreated cells 
as control. The statistical significances between the groups were represented by indicating 
the encompassed lines with the number of (*) sign.  The level of significance was set to p < 
0.05 (one-way ANOVA followed by Tukey's multiple comparison test method). Each bar 
represents the mean % ± SD (n=4) 
 
In case of both celly types before TmAb preincubation, covalently TmAb 
modified NPs showed the derscernable shifts in fluorescence compared to 
unmodified NPs as well as physically adsorbed TmAb modified NPs. However, 
covalent attachment of the ligand to the NPs was not found to significantly improve 
the cellular uptake in comparison to the NPs that were physically attached with the 
ligand.  
 
5.6.1.2. Cellular uptake after TmAb preincubation 
5.6.1.2.1. Coum-6 loaded NPs uptake in TmAb preincubated MCF-7 cells 
In this experiment, HER2 moderate expressed MCF-7 cells were incubated 
with TmAb before treatment with different types of Coum-6 loaded NPs and then 
continued as stated above. Figure-5.12 represents the comparative fold increases in 
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MFI for TmAb preincubated untreated MCF-7 cells and the preincubated cells 
treated with Coum-6 containing plain NPs, TmAb modified NPs, BS3-TmAb 
modified NPs. After 24 hrs incubation with respective NPs, non-specific cell uptake 
of TmAb free Coum-6 loaded NPs was reported with 46.72±6.02 folds increase in 
MFI for MCF-7 cells which was found in similar range as reported with same NPs 
uptake without TmAb preincubation. However, treatment with TmAb modified 
Coum-6 loaded NPs showed a slight reduction in uptake for the physically adsorbed 
(62.98±13.73 MFI) and covalently attached (68.46±8.49 MFI) TmAb modified 
coumarin-6 loaded NPs compared to the relative MFI found for the treatment gourps 
with no TmAb preincubation. 
 
Figure-5.12: Bar diagram indicating the fold increase of MFI for TmAb preincubated 
untreated MCF-7 cells and the TmAb preincubated MCF-7 cells treated with Coum-6 
containing plain NPs, TmAb modified NPs, BS3-TmAb modified NPs. Fold increase was 
calculated considering MFI of untreated cells as control. The statistical significances 
between the groups were represented by indicating the encompassed lines with the number 
of (*) sign.  The level of significance was set to p < 0.05 (one-way ANOVA followed by 
Tukey's multiple comparison test method). Each bar represents the mean % ± SD (n=4) 
 62 
5.6.1.2.2. Coum-6 loaded NPs uptake in TmAb preincubated SKBR-3 cells  
Similarly, HER2 overexpressed SKBR-3 cells were preincubated with TmAb 
and then treated with different types of Coum-6 loaded NPs treatment. Figure-5.13 
shows the relative fold increases in MFI for TmAb preincubated untreated SKBR-3 
cells and the preincubated cells treated with different NPs. 
 
Figure-5.13: Bar diagram indicating the fold increase of MFI for TmAb preincubated 
untreated SKBR-3 cells and the TmAb preincubated SKBR-3 cells treated with Coum-6 
containing plain NPs, TmAb modified NPs, BS3-TmAb modified NPs. Fold increase was 
calculated considering MFI of untreated cells as control. The statistical significances 
between the groups were represented by indicating the encompassed lines with the number 
of (*) sign.  The level of significance was set to p < 0.05 (one-way ANOVA followed by 
Tukey's multiple comparison test method). Each bar represents the mean % ± SD (n=4) 
 
Non-specific cell uptake of TmAb free Coum-6 loaded plain NPs was found 
with 41.65±7.63 folds increase for TmAb preincubated SKBR-3 cells after 24 hrs 
incubation which followed the similar range as reported with same NPs uptake 
without TmAb preincubation. However, fold increases in MFI for both [TmAb-NP 
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(Coum-6)] and [TmAb-BS3-NP (Coum-6)] were reduced significantly to 37.46±9.31 
MFI and 39.80±10.12 MFI after preincubation of SKBR-3 cells with TmAb. 
The fold increases in MFI for both [TmAb-NP (Coum-6)] and [TmAb-BS3-
NP (Coum-6)] were reduced significantly after preincubation of HER2 
overexpressed cells with TmAb after 24 h incubation. However, non-specific cell 
uptake of TmAb free Coum-6 loaded NPs in both cells was found in a similar range 
as reported with same NPs uptake without TmAb preincubation. In addition, HER2 
moderate expressed cells showed comparatively higher uptake for modified NPs 
compared to HER2 overexpressed cell lines in both conditions. Finally in both cell 
types, the overall uptake of TmAb modified NPs was declined after TmAb 
preincubation except unmodified NPs. This indicates a lack of selective binding 
receptors that were already saturated by TmAb preincubation. 
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5.6.2. Uptake study by CLSM 
The cellular uptake of NPs in MCF-7 and SKBR-3 cells was further 
investigated by CLSM to visualize the internalization of NPs into the cell 
cytoplasmic region and confirm the targeting efficiency of TmAb of the NPs. CLSM 
images provided actual scenario of cellular uptake for Coum-6 loaded PLGA NPs 
with and without TmAb conjugation in SKBR-3 and MCF7 cells after 24 hrs 
incubation. The nuclei of cells were stained blue with DAPI while the NPs consisted 
green fluorescence due to the emission produced by Coum-6 dye. Figure-5.14 listed 
all the merged images of both channels, where row-A and row-B represent the 
cellular uptake in SKBR-3 and MCF-7 cells, respectively after treating with Coum-6 
loaded plain, physically, and covalently attached TmAb modified NPs.  
 
Figure-5.14: Representative overlapped CLSM images for the cellular uptake of fluorescent 
Coum-6 loaded NPs with and without TmAb conjugation comparing untreated cells. Upper 
(A, B, C, and D) and lower (E, F, G, and H) rows are for HER2 overexpressed SKBR-3 and 
HER2 moderate expressed MCF-7 cells respectively. Blue color represents the DAPI stained 
nuclei which are encompassed by green fluorescence for the groups treated with Coum-6 
loaded NPs. All iImages’ magnification objectives: A-Apochromal 63x/1.2 W corr.  
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5.7. HER2 Expression 
To measure the amount of HER2 expression on HER2 dependent cells after 
treating with different formulations; flow cytometry, western blot and fluorescence 
microscopic studies were performed. 
 
5.7.1. Flow cytometry study 
The main purpose of staining all the cell groups with anti-HER2 FITC Ab 
was to quantify the amount of free HER2 receptor remaining on the cell surface after 
treatment with different formulations.  
 
5.7.1.1. Effect of incubation time for treating the cells with different 
formulations 
Incubation time for the treatment of cells with different formulations is an 
important parameter to evaluate the HER2 expression on the cells. Both cell types 
were treated with the formulations for 24 and 48 hrs. 
 
5.7.1.1.1. HER2 expression in MCF-7 cells 
Primarily, HER2 moderate expressed (MCF-7) cells were treated with TmAb 
modified plain NPs and various amounts of filtered TmAb for 24 and 48 hrs. Figure-
5.15 shows the relative MFI of MCF-7 cells for different treatment groups according 
to the time of incubation. Similar expression levels for HER2 were observed after 24 
hrs treatment. However, the level of HER2 expression was found to be higher after 
48 hrs incubation compared to 24 hrs incubation with the formulations. In addition, 
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the treatment of cells with the formulations for 48 hrs were found to lower the HER2 
expression compared to untreated cells that were stained with anti-HER2 FITC Ab. 
 
Figure-5.15: Time dependent HER2 expression of MCF-7 cells for different treatment 
groups (n=2) 
 
5.7.1.1.2. HER2 expression in SKBR-3 cells 
Following the same treatment conditions as MCF-7 cells, HER2 
overexpressed SKBR-3 cells were also treated with different amounts of filtered 
TmAb and TmAb modified plain NPs for 24 and 48 hrs. As observed in figure-5.16, 
nearly similar HER2 expression levels were observed for different treatments after 
24 hrs incubation. Higher HER2 expression levels were observed after 48 hrs 
incubation compared to 24 hrs. However, less HER2 expression was observed after 
48 hrs treatments of cells with the formulations.  
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Figure-5.16: Time dependent HER2 expression of SKBR-3 cells for different treatment 
groups (n=2) 
 
After time dependent HER2 expression experiments performed, it was 
observed that HER2 expression was increased by time in both cell types. In fact, the 
both cell types treated with different TmAb concentration were found higher after 48 
hrs compared to 24 hrs. However, HER2 expression was found lower after 48 hrs 
treatment with TmAb modified plain NPs that was not found to be reduced after 24 
hrs. Afterwards, I decided to continue with 48 hrs treatment of both cell types with 
other formulations.     
 
5.7.1.2. Effect of different formulations after 48 hrs incubation 
HER2 expression for both cell types was observed again for 48 hrs 
treatments with different NP formulations, filtered TmAb, free Doc, and Herceptin
®
. 
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In order to measure the effects of treating different formulations, dot plots and 
histograms were also considered. 
 
5.7.1.2.1. HER2 expression in MCF-7 cells 
Figure-5.17 shows the comparative dot plots and histograms for 48 hrs 
treatments of MCF-7 cells with different formulations comparing with the untreated 
groups. The detector was selected based on the absorption/emission wavelength of 
anti-HER2 FITC Ab. The experiments were repeated four times using the same 
setting with some minimum adjustment. 1.5x10
5
 live cells were initially considered 
for all the treatment groups. Less then 5% of gated population was considered for 
auto fluorescent of untreated unstained cells. Above that value the instrument 
counted the percentage of fluorescence as mean fluorescence intensity. All cell 
population without gate was accounted to have mean fluorescence intensity. The 
shift in fluorescence is evident from the diagrams. 
Untreated unstained MCF-7 cells 
  
Untreated MCF-7 cells stained with anti-HER2 FITC 
  
Anti-HER2 FITC stained MCF-7 cells treated with Herceptin
®
 (250µg) 
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Anti-HER2 FITC stained MCF-7 cells treated with filtered TmAb (250µg) 
  
Anti-HER2 FITC stained MCF-7 cells treated with Doc (10µg) 
  
Anti-HER2 FITC stained MCF-7 cells treated with plain NPs [NP] (2mg) 
  
Anti-HER2 FITC stained MCF-7 cells treated with TmAb modified plain NPs [NP-TmAb 
(25µg equivalent)] 
  
Anti-HER2 FITC stained MCF-7 cells treated with Doc loaded NPs (NP-Doc) (2mg) 
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Anti-HER2 FITC stained MCF-7 cells treated with Doc loaded TmAb modified NPs [NP-
Doc-TmAb (25µg equivalent)] 
  
 
Figure-5.17: Dot plots and histograms for untreated unstained, untreated stained MCF-7 
cells, and stained MCF-7 cells ater 48 hrs treatment with filtered TmAb, Herceptin
®
, Doc, 
and different NP formulations (n=4) 
 
Figure-5.18 shows the comparative differences for percentage of fluorescent 
cells expressing HER2 and MFI for each cell after various treatments. Fluorescent 
cells percentage (red colored bars) indicated the number of events which showed the 
mean fluorescent intensity (blue colored bars) for HER2 expression.   
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Figure-5.18: Relative % of MCF-7 cells showing HER2 expression after the treatment with 
different formulations (n=4) 
 
In figure-5.18, only 3.7% untreated cells showed the auto fluorescence. 
When untreated cells were stained with anti-HER2 FITC Ab, 30.60% of untreated 
MCF-7 cells were found with 22.23 MFI for HER2 expressions as a control. 
Whereas, Doc loaded TmAb modified NPs showed 22.52 MFI for HER2 
expressions with 20.33% positive cells among the total events. Relatively higher but 
insignificant HER2 expressions were found in case of the treatment with Doc (23.72 
MFI), plain NPs (25.09 MFI) and Doc loaded unmodified NPs (23.19 MFI) but the 
percentage of respective fluorescent cells was found to be higher in comparison to 
that of other treatments. However, HER2 expression for TmAb modified drug free 
NPs (21.28 MFI) was found in similar ranges as observed in case of Herceptin
® 
(20.94 MFI) and TmA (20.77 MFI). 
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5.7.1.2.2. HER2 expression in SKBR-3 cells 
Figure-5.19 shows the comparative dot plots and histograms for 48 hrs 
treatment of SKBR-3 cells with different formulations comparing the untreated 
groups following the treatment conditions similar to MCF-7 cells.  
 
Untreated unstained SKBR-3 cells 
  
Untreated SKBR-3 cells stained with anti-HER2 FITC 
  
Anti-HER2 FITC stained SKBR-3 cells treated with Herceptin
®
 (250µg) 
  
Anti-HER2 FITC stained SKBR-3 cells treated with filtered TmAb (250µg) 
  
Anti-HER2 FITC stained SKBR-3 cells treated with Doc (10µg) 
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Anti-HER2 FITC stained SKBR-3 cells treated with plain NPs [NP] (2mg) 
  
Anti-HER2 FITC stained SKBR-3 cells treated with TmAb modified plain NPs [NP-
TmAb (25µg equivalent)] 
  
Anti-HER2 FITC stained SKBR-3 cells treated with Doc loaded NPs (NP-Doc) (2mg) 
  
Anti-HER2 FITC stained SKBR-3 cells treated with Doc loaded TmAb modified NPs 
[NP-Doc-TmAb (25µg equivalent)] 
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Figure-5.19: Dot plots and histograms for untreated unstained, untreated stained SKBR-3 
cells, and stained SKBR-3 cells after 48 hrs treatment with filtered TmAb, Herceptin
®
, Doc, 
and different NP formulations (n=4) 
 
Figure-5.20 shows the comparative differences for percentage of cells 
showing MFI for HER2 expression for all treatments. In figure-5.20, only 4.49% 
untreated cells showed the auto fluorescence (21.75 MFI). When untreated cells 
were stained with anti-HER2 FITC Ab, 68.41% of untreated SKBR-3 cells were 
found with 72.53 MFI for HER2 expressions as a control. Doc loaded TmAb 
modified NPs showed 48.62 MFI for HER2 expression with 22.12% positive cells 
among the total events. Relatively higher HER2 expressions along with high 
percentage of fluorescent cells were found for the cells treated with Herceptin
®
 
(63.15 MFI, 68.97 %), TmAb (59.89 MFI, 65.39 %), and Doc (60.76 MFI, 49.64 %) 
compared to plain NPs (49.58 MFI, 27.36 %), TmAb modified plain NPs (45.34 
MFI, 34.38 %), Doc loaded unmodified NPs (59.64 MFI, 23.51 %), and Doc loaded 
TmAb modified NPs (48.62 MFI, 22.12 %). 
 75 
 
 
Figure-5.20: Relative % of SKBR-3 cells showing HER2 expression after the treatment 
with different formulations (n=4) 
 
The overall flow cytometry studies indicate an enhanced ligand-receptor 
interaction with NP system depending on the variables. The HER2 overexpressed 
cell lines showed significant reduction of HER2 expression compared to that of 
HER2 moderate expressed cells types.  
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5.7.2. Western blot study 
To verify the results from flow cytometry studies, the western blot 
experiment was considered to measure the relative HER2 protein expression levels 
after treating both cell types with same formulations maintaining similar conditions. 
Blotting membranes were incubated with the respective antibodies against HER2 
and β-actin. Figure-5.21 shows the relative HER2 protein expression levels for both 
cell types. 
 
Figure-5.21: Comparison of HER2 expression levels of breast cancer cell lines in western 
blots. After treating both cell types with same formulations, 30µg and 40µg equivalent 
proteins were taken from the prepared lysates to load in each well/lane. β-actin levels were 
determined to ensure equal amount of loading. (A) and (B) are the quantitative HER2 
protein expression of MCF-7 and SKBR-3 cells respectively. (C) and (D) represents the 
relative HER2 protein levels of both cell types which were measured using Image J 
software. The relative protein level of untreated cells was set as control. The statistical 
significances between the groups were represented by indicating the (*) sign.  The level of 
significance was set to p<0.05 (one-way ANOVA followed by Tukey's multiple comparison 
test method). Each bar represents the mean % ± SD (n=3) 
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Almost similar HER2 expression trend was observed in Western blot studies 
as reportes in flow cytometry studies with both cell types. Although a declining 
trend for HER2 protein expression was observed for the treatment of modified drug 
loaded NPs in moderate expressed cells, a significant reduction in protein expression 
level was noted in HER2 overexpressed cells.  
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5.7.3. Fluorescence microscope study 
To visualize the effects of Doc loaded TmAb modified NPs on HER2 
expression levels of both cell types, fluorescence microscopic study was considered. 
To achieve this, only TmAb and Doc loaded TmAb modified NPs were treated with 
both cell types following same treatment conditions as maintained in flow cytometry 
and western blot experiments. 
 
5.7.3.1. HER2 expression in MCF-7 cells 
Fluorescence images in figure-5.22 are demonstrating the specificity of 
TmAb binding and chemotherapeutic response in MCF-7 cells. 
 
 
Figure-5.22: Fluorescent images of MCF-7 cells for HER2 expression levels after 48 hrs 
treatment with TmAb and TmAb modified Doc loaded NPs. HER2 receptor expression is 
shown in green (anti-HER2 FITC labeled) and nuclei in blue (DAPI stained): (A-series) 
untreated cells, (B-series) TmAb-250µg, and (C-series) Doc loaded TmAb modified NPs-
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25µg equivalent. (A-1), (B-1), and (C-1) are shown for DAPI staining. (A-2), (B-2), and (C-
2) are shown for anti-HER2 FITC staining. (A-3), (B-3), and (C-3) are shown for overlaying 
their respective DAPI and anti-HER2 FITC stained. Fluorescence images were obtained 
using Olympus fluorescence microscope with 40X objective lens 
 
5.7.3.2. HER2 expression in SKBR-3 cells 
In figure-5.23, fluorescence images for HER2 expression levels after 48 hrs 
treatment of SKBR-3 cells with TmAb and TmAb modified Doc loaded NPs were 
shown.  
 
 
Figure-5.23: Fluorescent images of SKBR-3 cells for HER2 expression levels after 48 hrs 
treatment with TmAb and TmAb modified Doc loaded NPs. HER2 receptor expression is 
shown in green (anti-HER2 FITC labeled) and nuclei in blue (DAPI stained): (A-series) 
untreated cells, (B-series) TmAb-250µg, and (C-series) Doc loaded TmAb modified NPs-
25µg equivalent. (A-1), (B-1), and (C-1) are shown for DAPI staining. (A-2), (B-2), and (C-
2) are shown for anti-HER2 FITC staining. (A-3), (B-3), and (C-3) are shown for overlaying 
their respective DAPI and anti-HER2 FITC stained. Fluorescence images were obtained 
using Olympus fluorescence microscope with 40X objective lens. 
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5.8. Cell viability and toxicity studies 
Staining of both cell types after nano-formulation treatments was performed 
using Annexin V-FITC/ PI to evaluate the cell death followed by apoptosis. 
Comparative percentages of cell viability, cell death, apoptosis, and necrosis were 
meant to evaluate how the chemotherapeutic response worked after receptor-
mediated endocytosis of targeted and non-targeted nano-formulations into the cells 
cytoplasm. Relative gating on total cell population was considered based on the 
forward and side scattering histograms; and subsequently FACS data was analyzed 
based on the double staining of both cell types with Annexin V-FITC/PI.   
 
5.8.1. Moderate HER2 expressed cells: MCF-7 
In figure-5.24, the comparative percentages of live cells, cell death, necrosis 
and apoptosis data were represented in the dotplots upon respective treatments. Four 
uneven quadrants were considered to reflect the percentange of live cells in lower 
left, cell necrosis in upper left, cell early apoptosis in lower right, and cell death in 
upper right quadrants of the dotplots square.  
Upon treating MCF-7 cells with different treatment groups, the percentage of 
live cells was found in a range from 56.26±5.59% to 81.46±0.93%. Early apoptotic 
cell percentage was varied from 4.16±0.38% to 27.10±4.23%, whereas cell death via 
late apoptosis was observed within 8.11±1.30% to 17.10±3.04% range. However, 
cell necrosis range varied from 3.15±0.12% to 14.55±4.01%. 
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Figure-5.24: Evaluation of viability and toxicity in HER2 moderate expressed cells (MCF-
7) by flow cytometry upon 48 hrs incubation with culture media (3 controls plus untreated 
cells+Ann-V+PI), Herceptin
®
 (Her), TmAb, plain NPs (NP), TmAb modified plain NPs 
(TmAb-NP), free drug (Doc), drug loaded unmodified NPs [NP-(Doc)], TmAb modified 
drug loaded NPs [TmAb-NP(Doc)] 
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Figure-5.25 shows the relative evaluation of viability and toxicity in HER2 
moderate expressed cells (MCF-7) by flow cytometry upon 48 hrs incubation with 
different treatment groups. 
 
Figure-5.25: Relative evaluation of viability and toxicity in HER2 moderate expressed cells 
(MCF-7) by flow cytometry upon 48 hrs incubation with culture media (3 controls plus 
untreated cells+Ann-V+PI), Herceptin
®
 (Her), TmAb, plain NPs (NP), TmAb modified 
plain NPs (TmAb-NP), free drug (Doc), drug loaded unmodified NPs [NP-(Doc)], TmAb 
modified drug loaded NPs [TmAb-NP(Doc)] 
  
Upon treatment with different formulations after 48 hrs, MCF-7 cells showed 
a relative percentage of necrosis, death cells, early apoptosis, and live cell. The 
percentage necrotic cells for TmAb treatment was found higher compared to other 
treatments and untreated cells. The cell death and apoptotic cell percentages were 
found highest for the free drug. In addition, the early apoptosis was observed 
relatively higher with plain NPs and TmAb modified plain NPs compared to drug 
loaded unmodified and modified NPs. However, drug loaded TmAb unmodified and 
modified NPs showed relatively lower apoptotic rate than the drug free unmodified 
and modified NPs.  
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5.8.2. HER2 overexpressed cells: SKBR-3 
Figure-5.26 shows the comparative percentage of live cells, cell death, 
necrosis and apoptosis data was represented in the dotplots upon respective 
treatments with HER2 overexpressed cells. 
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Figure-5.26: Evaluation of viability and toxicity in HER2 overexpressed cells (SKBR-3) by 
flow cytometry upon 48 hrs incubation with culture media (3 controls plus untreated 
cells+Ann-V+PI), Herceptin
®
 (Her), TmAb, plain NPs (NP), TmAb modified plain NPs 
(TmAb-NP), free drug (Doc), drug loaded unmodified NPs [NP-(Doc)], TmAb modified 
drug loaded NPs [TmAb-NP(Doc)] 
 
The percentage of live cells was found in a range from 5567±1.21% to 
74.81% after treating SKBR-3 cells with different treatment groups. Early apoptotic 
cell percentage was varied from 6.98% to 23.24%, whereas cell death via late 
apoptosis was observed within 8.40±1.28% to 14.46±2.11% range. However, cell 
necrosis range varied from 5.53±1.54% to 9.63±2.95%. 
Followed by 48 hrs incubation with different treatment groups, the relative 
evaluation for viability and toxicity in HER2 overexpressed cells (SKBR-3) was 
shown in figure-5.27. 
 
 
Figure-5.27: Relative evaluation of viability and toxicity in HER2 overexpressed cells 
(SKBR-3) by flow cytometry upon 48 hrs incubation with culture media (3 controls plus 
untreated cells+Ann-V+PI), Herceptin
®
 (Her), TmAb, plain NPs (NP), TmAb modified 
plain NPs (TmAb-NP), free drug (Doc), drug loaded unmodified NPs [NP-(Doc)], TmAb 
modified drug loaded NPs [TmAb-NP(Doc)] 
  
Untrea
ted
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Necrotic Cells 8.92 9.63 7.96 6.64 5.91 5.53 8.63 6.74
Dead Cells 9.30 9.27 11.47 14.46 8.40 9.48 10.49 11.87
Live Cells 74.81 65.33 68.47 55.67 68.98 68.10 67.97 68.17
Apoptotic Cells 6.98 15.78 12.11 23.24 16.72 16.90 12.92 13.23
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In summary, highest percentage of necrotic cells was observed for treating 
HER2 overexpressed cells with Herceptin
®
 although not significantly different from 
necrotic cell percentages observed in the untreated cells and other treatment groups. 
The percentage of cell death and apoptosis was found higher with free drug 
treatment as followed similar trend in moderate expressed cells. Regardless of free 
drug treatment, TmAb alone and TmAb modified drug loaded NPs showed relatively 
higher percentage of dead cells than other controls. However, early apoptosis was 
observed relatively lower for drug loaded modified and unmodified NPs. In addition, 
the apoptosis rate was observed higher in plain NPs and TmAb modified plain NPs 
compared to drug loaded unmodified and modified NPs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 86 
 
 
 
6. DISCUSSIONS 
 
6.1. Size, PDI, and ZP 
Getting therapeutic agents internalized into target cells is an important 
physicochemical criterion for efficient targeted drug delivery system prior to in vivo 
application. Among all internalization mechanisms, endocytosis plays an important 
role in targeted delivery. Endocytosis is the bulk active transport process to 
internalize small molecules following two main endocytic mechanisms such as 
phagocytosis and pinocytosis (97). Phagocytic cells (e.g. macrophages, neutrophils, 
dendritic cells etc.) mediated cellular internalization is mostly involved with NPs 
with larger size (98). Adsorption or receptor mediated internalization is the main 
mechanism of pinocytosis, which is more related to NPs uptake by the cells 
following different pathways such as macro pinocytosis, clathrin, caveolin 
dependent or independent pinocytosis (99). Size, PDI, and surface charge of 
polymeric NPs are likely the primary physicochemical variables, which govern the 
endocytosis dependent cellular uptake.  
In this study, freeze-drying is the key step to produce dry NPs. Size of the 
NPs of all formulations was found to be larger after freeze-drying process compared 
to that of NPs before freeze-drying. Freeze-drying could be a reason to increase the 
size of NPs. The generation of freeze-drying stress is an important factor to be 
considered during freeze-drying process. The increase in size of NPs following 
freeze-drying could be attributed to the disruption of electrostatic repulsion between 
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the particles by freeze-drying stress. This can be responsible to yield higher particle-
particle aggregations (Table-5.1). The high PDI value observed from freeze-dried 
NPs indicates the presence of higher aggregation tendency leading to poly-dispersed 
larger particles. The PDI of NPs is a number after cumulative analysis calculated 
from a simple two-parameter fit to the correlation data. The maximum value of PDI 
equal to 1 demonstrates that the sample is associated with a broad size distribution. 
The PDI of our nano-suspension was in a low to moderate range, which 
demonstrated a more uniform size distribution. The ZP values shifted towards more 
negative after freeze-drying in a range to be appropriate for a pharmaceutically 
stable formulation. 
To minimize the particle-particle aggregations, 10% sucrose as 
cryoprotectant was used in the NP suspenstion. Utilizing cryoprotectant in the NP 
suspension offered NPs with a narrow size range and PDI, compared to the 
formulations without cryoprotectant before freeze-drying (Table-5.2). Similar trend 
was observed when these measurements were obtained after freeze-drying. The 
obtained lower average size and PDI values after freeze-drying is due to the addition 
of cryoprotectant in the NP suspension, which could possibly minimize the freeze-
drying stress in order to create steric stabilization. In addition, ZP values were found 
to be less negative after using 10% sucrose as cryoprotectant in the plain NP 
formulations compared to the formulation freeze-dried with no cryoprotectant. 
However, no significant correlation could be made after statistical evaluation of ZP 
values using cryoprotectant between the plain NP formulations before and after 
freeze-drying. 
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BS3 is one of the main variable components of targeted NP formulations. In 
case of size measurement, no significant differences were found after inclusion of 
BS3 in all plain NP formulations when freez-dried with 10% cryoprotectant (Table-
5.3). Similar PDI values were observed for the BS3 containing formulations before 
freeze-drying. ZP values of BS3 containing plain formulations with 10% 
cryoprotectant were observed to be less than -20mV. ZP values showed a more 
negative trend by increasing the amount of BS3 in NPs. However, using 
cryoprotectant in the BS3 included formulation was not found to interfere with the 
particle surface charge. Before and after freeze-drying, the ZP values of BS3 
containing batches did not follow any order or consistency. Based on the results 
obtained, no statistically significant differences were observed for surface charge 
after incorporation of different amounts of BS3.  
Doc loaded NPs were found to have a lower size compared to the plain NPs 
without drug loading; and size of the NPs was decreased with the increase in the 
concentrations of Doc initially used (Table-5.4). Both drug and PLGA polymer are 
hydrophobic in nature; and the hydrophobic interactions between them could 
condense the droplets during the NP preparation to yield a lower particle size. 
Precipitation of non-emulsified drug or polymer in aqueous phase during the solvent 
evaporation could be a probable reason to lessen the quantity of polymer or drug 
leading to lowering the yield of preparation or encapsulation efficiency, respectively 
(100). In Doc loaded NP formulations without BS3, the ZP values were stabilized 
towards more negative surface charge by higher concentration of the drug initially 
used to prepare the NPs. After freeze-drying the drug-loaded formulations with 
cryoprotectant, the surface charges shifted towards less negative compared to before 
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freeze-drying. This could be due to shielding of negative charges of drug (hydroxyl 
groups) by cryoprotectant and PLGA itself. However, no significant differences 
were found after statistical analysis. 
Similar trend of decreasing size of Doc loaded NPs was also observed with 
increasing the initial concentration of drug used in the BS3 included formulations 
(Table-5.5). Addition of BS3 into the aqueous phase of the formulation could be a 
possible reason to lower the particle size since it could lead to more porous surface 
area of NPs. BS3 consists of an amine-reactive N-hydroxysulfosuccinimide (NHS) 
ester at each end of an 8-carbon spacer arm and is soluble up to ~100mM in water as 
it contains the hydrophilic sulfonyl moiety. Thus, BS3 could be able to lead the 
diffusion of drug and polymer from the matrix to either solvent during preparation or 
water during washing steps. Similar PDI values were observed for the BS3 
containing formulations and NPs without BS3, which demonstrates that the presence 
of BS3 in the formulations does not interfere with the size distribution profile. 
Considering BS3 as an important variable for targeted NP formulations, ZP values 
of the BS3 containing drug-loaded formulations were observed to be slightly more 
negative compared to the formulations with no BS3 before freeze-drying. This could 
be accounted for the presence of residual sulfo-NHS (water soluble N-hydroxy 
sulfo-succinimide) in the nano-suspension and Doc itself.  
A significant increase in the average hydrodynamic diameter of all NPs was 
observed after TmAb attachment, which was in the range of 300-450 nm depending 
on the formulation composition (Table-5.6). TmAb functionalization did not show 
any significant change in terms of PDI. However, a significant change in surface 
charge was observed for the NPs after TmAb attachment and the change shifted 
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towards more positive surface charge to nearly neutral. This result indicates the 
presence of positively charged Ab on the NP surface. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 91 
6.2. Drug loading and entrapment efficiency 
Compared to theoretical amount of drug to be loaded per mg of NPs, 
practically loaded drug into the NPs was found very low (table-5.7 and table-5.8). 
Reduced size of the particle due to hydrophobic interactions between drug and 
polymer can also result in low drug loading. In addition, insufficient polymer or 
drug amount due to precipitation during solvent evaporation can also be involved in 
reduced encapsulation (100).  Since Doc is associated with higher affinity for 
organic solvents, it could diffuse out of the polymer matrix of unstable emulsion 
droplets into the organic solvent during preparation. This could also be a possible 
reason for low entrapment efficiencies (101).  
The loading of drug and EE are extensively correlated with one another 
(figure-5.1 and figure-5.2). By increasing the concentration of the drug, loading may 
increase but the entrapment efficiency may be reduced (102). The observation can 
be clarified by the fact that osmotic pressure gap between two phases (inner and 
outer) could be changed due to higher concentration of drug into the NPs. Some 
damage to the formed quasi-emulsion droplets could occur due to the change 
between two phases. This could be the reason for the escape of drug molecules from 
the inner phase of emulsion droplets to outer phase (103). Drug entrapment 
efficiency can be decreased since higher amount of initial drug content in the 
formulation may not be proportional to the higher amount of entrapped amounts of 
drug (104, 105). When the maximum loading capacity of NPs is achieved; further 
increase of initial drug concentration can reduce the entrapment efficiency (106). 
Taking into account these considerations, our results demonstrated similar trend 
when using higher concentration of drug in the formulations with and without BS3. 
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Besides, NPs were prepared following o/w emulsion technique where the drug is 
associated with poor water solubility. Poor water-soluble drug is supposed to favor 
the oil or organic phase during o/w emulsion procedure. Such higher affinity of 
poorly water-soluble drug to the inner or oil phase could favour higher loading 
compared to water soluble drugs (107). 
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6.3. TmAb quantification and attachment to the NPs  
Higher TmAb attachment efficiency was observed with lowest amount of 
BS3 used in the formulations (table-5.9). However, TmAb attachment followed by 
adsorption method was also found higher, which was comparable with attached 
TmAb amount followed by covalent method. For further experiments, BS3 was 
applied at the amount of 1.5 mg per formulation since it showed the highest Ab 
attachment efficiency. 
The results after using variable amounts of TmAb and BS3 pre-activated NPs 
showed a comparative TmAb attachment amount and attachment efficiency per mg 
of NPs (table-5.10). Relatively higher amount of TmAb was attached with higher 
amount of Ab initially used in the formulation. However, the attachment efficiencies 
upon treating different TmAb amounts did not show any significant difference. 
Reasonably, the loss of excess unbound TmAb was found higher when higher 
amount of TmAb used for the attachment. 
Different incubation conditions also showed a relative TmAb attachment 
efficiency (table-5.11). Relatively higher TmAb attachment was observed when the 
conjugation was performed at room temperature compared to the conjugation at 4
ᵒ
C. 
In conclusion, covalently attached TmAb modification for BS3 included 
plain NPs showed higher amount of Ab attachment compared to physically adsorbed 
TmAb modified NPs. However, physically adsorption method showed relatively 
higher percentage of attachment than covalently conjugated TmAb modified Doc 
loaded NPs in both incubation conditions. Non-specific elestrostatic interaction 
between the ligand and NP surface could be attributed to increase the TmAb 
attachment with plain NPs with no crosslinking agent. In addition, less TmAb 
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binding to the drug loaded NPs could be due to less amount of BS3 available on the 
surface of the drug loaded NPs. Since, the percentage of TmAb attachment 
efficiency was found higher at room temperature incubation, I decided to continue 
TmAb modification of NPs at room temperature for rest of the studies. Considering 
room temperature as a standard condition, the TmAb attachment among all the NP 
formulations followed this trend: TmAb-BS3-NP > TmAb-NP > TmAb-BS3-
Doc(3)-NP > TmAb-BS3-Doc(0.75)-NP > TmAb-BS3-Doc(1.5)-NP. No significant 
difference was observed after assessing TmAb attachment levels with the respective 
NP formulations. 
The structural modification of BS3 activated formulations with TmAb were 
confirmed by FTIR and SDS-PAGE studies (figure-5.3 and figure-5.4).  
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6.4. Targeting efficiency: Uptake studies 
Doc itself is not fluorescent and Coum-6 was used as a dye to be loaded into 
the NPs to evaluate the targeting efficiency of TmAb modified NPs. The loading and 
EE of Coum-6 into the PLGA NPs were found comparatively higher than the drug 
loaded NP formulations (table-5.8 and table-5.12). The reason for higher loading of 
Coum-6 over Doc into the PLGA NPs could be attributed to the molecular weight 
difference, since the molecular weight of Coum-6 (350.43 g/mol) is about half of 
Doc (807.88 g/mol).  In addition, the partition coefficient of drug and Coum-6 
between internal and external phases in o/w emulsion could be different for the 
entrapment into the NPs. Because, the viscosity of the solution would be higher after 
dissolving high molecular weight drugs into the solvent, which might have reduced 
the diffusion rate of drug into the external aqueous phase of o/w emulsion. This slow 
extruding of solvent could result a slow precipitation of polymer to form a concrete 
external phase of emulsion droplet. Therefore, more time is required for the drug 
molecules to come into aqueous phase which ultimately results a reduced EE (64). 
Although these considerations might affect the loading, EE, and ultimately the 
release of the drug/Coum-6 from NPs they may not influence the purpose and 
outcome of our study, which is the investigation of NP uptake by the cells not the 
uptake of free drug or dye. Finally, two different NP treatment conditions were 
considered to evaluate the cell uptake studies in both cell types: one was without 
TmAb preincubation of cells and other was after TmAb preincubation of cells.  
For the treatment of TmAb modified Coum-6 loaded NPs both cells with no 
TmAb preincubation, the shift in fluorescence was found relatively higher (right 
side) (figure-5.7 and figure-5.10). This is because these NPs consist of TmAb ligand, 
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which could better recognize the HER2 receptor for uptake. Covalently modified 
NPs showed comparatively higher uptake in both cell types compared to plain and 
physically adsorbed TmAb modified NPs, although physically absorbed NPs 
contained a high percentage of TmAb on the surface. However, covalent attachment 
of the ligand to the NPs was not found to significantly improve the cellular uptake in 
comparison to the NPs that were physically attached with the ligand. Despite the 
higher Ab incorporation after physical adsorption, the possible reason of lower 
uptake could be detachment of loosely attached Ab from the particle surface during 
the treatment process (91). This indicates the necessity of covalent conjugation for 
the targeted vehicle, which can  maintain the intactness of desired drug delivery 
system. The overall uptake studies in both cell types with no TmAb pre-incubation 
indicated higher fold increase in MFI for TmAb functionalized nano-formulation 
compared to its plain or unmodified subtype. Thus, higher cellular uptakes 
confirmed the enhanced targeted receptor mediated cellular recognition and 
endocytosis. 
Followed by TmAb preincubation of both cells with TmAb, non-specific cell 
uptake of TmAb free Coum-6 loaded NPs in both cells was found in a similar range 
after 24 hrs incubation as reported with NPs uptake without TmAb preincubation 
(figure-5.12 and figure-5.13). However, fold increases in MFI for both [TmAb-NP 
(Coum-6)] and [TmAb-BS3-NP (Coum-6)] were reduced significantly after 
preincubation of HER2 overexpressed cells with TmAb. This could be attributed to 
the lack of sufficient free binding sites of HER2 receptors available for TmAb-NPs, 
which may already be preoccupied during the TmAb preincubation. In contrast, 
HER2 moderate expressed cells showed comparatively higher uptake for physically 
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adsorbed and covalently attached TmAb modified Coum-6 loaded NPs compared to 
HER2 overexpressed cell lines. MCF-7 cells lack abundant HER2 receptors to bind 
with TmAb. Insufficient HER2 receptors on MCF-7 cell surface and nonspecific 
cellular binding could be the possible reasons for higher NPs uptake. In addition, the 
positive surface charge of [TmAb-NP (Coum-6)] formulations could provide the 
incentive aid for better interection with negatively charged cell membrane, leading 
to more NPs to be internalized (108) (109). However, the fold increases in MFI were 
found to be lower for both [TmAb-NP (Coum-6)] and [TmAb-BS3-NP (Coum-6)] 
after preincubation of MCF-7 cells with TmAb, compared to the condition without 
TmAb preincubation. It could be due to unavailable or preoccupied HER2 receptors 
for HER2 overexpressed cells as dicussed above. In case of both cell types, the 
overall binding efficacy between TmAb modified NPs and cells declined after 
preincubation with TmAb. However, similar binding trends (as mentioned earlier for 
without preincubation condition) were observed for TmAb free NPs after TmAb 
preincubation due to nonspecific binding. As a result of this investigation, it could 
be concluded that free targeting ligands could occupy the binding sites of the 
specific receptors leading to inhibition of targeted receptor mediated endocytosis. 
CLSM images also confirm the the comparative NPs uptake in MCF-7 and 
SKBR-3 cells depending on the presence of TmAb in NP formulations. From the 
figure-5.14, it can be assumed that the fluorescence of Coum-6 loaded TmAb 
modified NPs (green) are localized around the cytoplasm, which indicates the 
binding of NPs to the cell surface for subsequent endocytosis. Fluorescent intensity 
is varied depending on the formulations. Fluresencent intensity of the cells uptaking 
the fluorescent NPs also depends on the concentration or amount of the dye used to 
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prepare the NPs, which maintained constant in all the formulations. The fluorescent 
NPs uptake into the cells is expressed as the intensity   of the fluorescent dye and 
depends on the concentration used. In the CLSM image, non-specifice binding 
between unmodified Coum-6 loaded NPs to both cells was not visibly profound as 
indicated in flow cytometric analysis. In the literature, it has been stated that 
misinterpretation could occur for cellular uptake of fluorescent NPs because of 
leaching or dissociation of the dye into the cell suspension medium. This leaching in 
the cell suspension with improper washing steps could extrapolate an enhanced 
cellular uptake (3). However, a comparative fluorescent intensity of the Coum-6 can 
be visualized to comprehend the influence of ligand on NPs for receptor mediated 
binding to the cell surface. 
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6.5. Assessment of HER2 expression 
HER2 antigen or receptor is a surface marker on breast cancer cells. Anti-
HER2 FITC antibody can recognize and bind to stain the external domain of this 
protein (HER2) present on cell surface such as moderately expressing MCF7 and 
overexpressing SKBR-3 cell lines. To optimize the best incubation time for treating 
both cell types with different formulations, initially two different time points (24 and 
48 hrs) were considered. In addition, the level of HER2 expression of untreated cells 
(control: stained with anti-HER2 FITC Ab) was also evaluated to support this time 
dependent factor after two different time periods since HER2 expression was found 
comparatively higher in both untreated cell types (control) after 48 hrs than 24 hrs 
(figure-5.15 and figure-5.16). In addition, a reduced HER2 expression was observed 
after 48 hrs for treating the cells with TmAb of different amounts (250 µg and 500 
µg) and TmAb modified drug free NPs (25 µg TmAb equivalent amounts of NP). 
Depending on the results of this time dependent experiment, 48 hrs incubation times 
was considered for further investigation. 
After 48 hrs incubation of MCF-7 cells, higher HER2 expressions and 
fluorescent cell percentages were found in case of the treatments with Doc, plain 
NPs and Doc loaded unmodified NPs compared to other treatments (figure-5.18). 
Although cytotoxic drug or it’s delivery through NPs is designated to kill or stop the 
proliferation of cancer cells by interfering with microtubular functions in cytoplasm, 
still cancer cells are able to  survive in different pathways. Multiple drug resistance, 
alternative cell signaling pathways might help cancer cells to stay alive and enhance 
further growth. In the results, Doc and Doc loaded unmodified NPs have been found 
to increase HER2 expression that could be attributed to the increased generation of 
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HER2 receptors for survival of MCF-7 cells. However, the percentage of cells 
showing HER2 expression was also higher which could be comparable with that of 
other treatment groups. Increased HER2 expression in MCF-7 cells observed for 
unmodified plain NPs could be further investigated although it was insignificant. 
The resulted reduced percentage of MCF-7 cells showing HER2 expression 
observed for both TmAb modified plain and TmAb docetaxel loaded NPs indicates a 
better cellular recognition as well as less free ligand binding sites or reduced HER2 
receptors. 
Followed by similar experiments (48 hrs incubation) in HER2 overexpressed 
SKBR-3 cells, a relatively higher HER2 expression along with high percentage of 
fluorescent cells was observed for Herceptin
®
, TmAb, and Doc compared to that of 
plain NPs, TmAb modified plain NPs, Doc loaded unmodified NPs, and Doc loaded 
TmAb modified NPs (figure-5.20). It was noted that neither Herceptin
®
 nor filtered 
TmAb could reduce the significant HER2 expression although these are clinically 
recommended mAb therapy for HER2 positive breast cancer. However, plain NPs 
showed relatively less percentage of fluorescent cells compared to TmAb modified 
drug free NPs although their levels of HER2 expression were in similar range. 
Reasonably, drug loaded unmodified and modified NPs showed reduced HER2 
expressions where modified one was found with more prominent reduction for 
HER2 expression than the unmodified one. It is important to notice that TmAb 
modified drug loaded NPs resulted the lowest percentage of cells which is also 
comparable with the reduced percentage of cells observed for plain and drug loaded 
unmodified NPs. Some explanations can be made for the reasons of reduced 
percentage of cells showing HER2 expression due to these respective treatments. For 
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TmAb modified drug loaded NPs, it was expected as it consists of targeting ligand 
that can better recognize overexpressed HER2 receptors for subsequent binding and 
endocytosis. In case of drug loaded unmodified NPs, the significant reduction of cell 
percentage could be related to the amount NPs excessively entrapped into the cells 
due to the size dependent cellular endocytosis. But, the resulted higher HER2 
expression could be due to lack of targeting ligand in the respective NP formulation. 
Furthermore, the reduced HER2 expression resulted with TmAb modified and 
unmodified Doc loaded NPs could also be associated with chemotherapeutic 
responses after endocytosis due to initial release of drugs into cell cytoplasm. 
In addition, the reason for reduced HER2 expression levels could be involved 
with the physicochemical characteristics of NPs such as size, surface charge, and the 
presence or absence of targeting ligand. This also because, the Ab modified NPs 
were almost double in size and positive to neutral in charge compared to the 
negatively charged unmodified NPs. If the size of NPs is high, it may inadequate for 
these to be internalized into the cells. However, electrostatic interaction may 
expedite the adherence of modified NPs to the cell surface. In addition, extracellular 
region of HER2 receptor involves four domains: two cysteine-rich regions (domain-
II and -IV) and two ligand binding regions (domain-I and -III). Domain-I consists of 
amino-terminal that possesses positive charge in nature (110). Due to negative 
charges of unmodified NPs, nonspecific electrostatic interactions could be the 
possible mechanism to occupy the abundant positively charged terminal ends of the 
receptors in overexpressed SKBR-3 cells. As a result, the percentage of cells 
showing HER2 expression was found lower to be stained with anti-HER2 FITC Ab 
after treating the overexpressed cells with unmodified docetaxel loaded and plain 
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NPs. However, the flow cytometry studies demonstrated the enhanced ligand-
receptor interaction with nanoparticulate system depending on the variables. After 
treating different formulations, the overexpressed HER2 cell lines showed a 
comparative reduction for HER2 expression than HER2 moderate expressed cells.  
The overall Western blot studies revealed a declining trend of HER2 protein 
expression levels in  cells treated with  TmAb modified plain NPs (NP-TmAb), Doc 
loaded NPs (NP-Doc), and Doc loaded TmAb modified NPs (NP-Doc-TmAb) 
compared to other treatment groups and control (untreated cells). However, a 
significant decrease in HER2 protein level was found for the treatment of SKBR-3 
cells with drug loaded Ab modified NPs. Although plain NPs showed a significant 
reduction of HER2 expression with both cells in flow cytometry studies, the 
opposite results were observed in western blot studies. It was somewhat higher or 
equivalent to relative HER2 protein levels observed in case of untreated cells. It 
could be attributed to the inertness or only masking of cells by the negative charged 
plain NPs due to electrostatic attachment. Due to masking of cells surrounded by the 
plain NPs or inadequate HER2 receptors due to shielding could be a reason to hinder 
the binding of fluorescent anti-HER2 FITC antibody to the extracellular HER2 
receptors. But in western blot studies, only the protein of interest (HER2) was 
isolated and displayed for the level of its expression on the blotting membrane. In 
this case, no masking of cell surface or cell surface receptors by NPs was possible 
due to non-specific electrostatic or other possible interactions, as reported in flow 
cytometric analysis. As a result, actual protein expression level was determined for 
the efficacy of different NP treatment groups.   
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Similarly in the images from fluorescent microscope (figure-5.22 and figure-
5.23), the cell membrane of both cell types with a comparatively lower HER2 
expression was observed for TmAb modified Doc loaded NPs treatment compared 
to the untreated cells and TmAb treatment. This demonstrates the specific binding 
between the ligand and the available HER2 receptors on cell surface. 
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6.6. Evaluation of chemotherapeutic response 
Apoptosis is a normal physiological process of a programmed cell death that 
involves tumor suppression (111). Ideally, assessing early or late apoptosis rate of 
tumor cells relative to their viability percentages was considered to evaluate the 
respective responses of treatment groups depending on the treating materials. Since 
Doc is a cytotoxic drug of choice, the chemotherapeutic responses of free drug and 
drug loaded NPs were also compared with other treatment options.   
Figure-5.25 and figure-5.27 show the relative evaluation of viability and 
toxicity in HER2 moderate expressed (MCF-7) and overexpressed (SKBR-3) cells 
after treatment where the cell viability was higher for the untreated cells. However, 
the cell viability percentages went down for other treatment groups. Treatment of 
both cells with Doc was found with lowest cell viability. It could be attributed to the 
direct effects of cytotoxic drug in contact with cells. Almost similar cell viability 
percentages were observed for drug loaded unmodified NPs, TmAb modified plain 
NPs, TmAb modified drug loaded NPs respectively. 
 Upon treatment with different formulations, both cell types were observed 
for necrosis percentage. The percentage of necrotic cells for TmAb treatment was 
found to be extensively higher in MCF-7 cells compared to other treatments and 
untreated cells. TmAb was purified from the clinical formulation (Herceptin
®
) and 
the presence of impurities into the filtered TmAb could be a possible reason for  
more necrosis. However, the difference in necrosis was not significant. The highest 
necrotic cells were found in clinically recommended Herceptin
®
 treatment with 
HER2 overexpressed cells although it was not significantly different from untreated 
cells and other treatment groups. 
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It is more important to observe the chemotherapeutic responses of different 
treatment groups in HER2 moderate expressed cells. The percentages of cell death 
and apoptosis may also be considered for evaluating the chemotherapeutic responses 
since considering the live cells only could not be an accurate evaluation. From 
analysis, the cell death and apoptotic cell percentages were found highest for the free 
drug.  
In both cells, early apoptosis was observed relatively higher with plain NPs 
and TmAb modified plain NPs than drug loaded unmodified and modified NPs. 
Suitable size of the plain unmodified NPs for nonspecific binding as well as 
internalization into the cells could trigger the early apoptosis. In addition, 
nonspecific electrostatic interactions between positively charged TmAb modified 
plain NPs and negatively charged cell surface could contribute to higher percentage 
of apoptotic cells. However, drug loaded TmAb unmodified and modified NPs 
showed relatively lower apoptotic rate than the drug free unmodified and modified 
NPs. Inadequate release or access of drug from the NP matrix could be attributed to 
the reduced apoptosis compared to free drug treatment group. However, results for 
the treatments with drug free plain NPs may not be related to excessive toxicity to 
some extent (112). 
 
 
 
 
 
 
 
 
 106 
 
 
 
7. CONCLUSION 
 
The ester-ended drug loaded NPs with low molecular weight result in a 
desirable size range of 100-200 nm and is suitable for effective intracellular uptake 
(113). Fenestration or pore sizes in tumor microvasculature vary between 100 nm 
and 780 nm (89). Many studies have revealed that the suitable or effective size of 
nanocarriers below 400 nm was found to have a better extravasation and 
accumulation (114). Considerable increase in size of NPs was observed when NPs 
were redispersed after freeze-drying due to the aggregation of particles. Achieving 
such a higher size range of freeze-dried NPs following redispersion in any media is a 
major drawback in emulsification-solvent evaporation method. Our aim was to 
overcome this limitation using cryoprotectants in the drug loaded formulations. The 
results demonstrated the average size range below 400 nm after freeze-drying when 
10% sucrose was used as a suitable cryoprotectant in the formulations. Addition of 
cryoprotectant not only protected NPs from strong aggregation but also reduced the 
energy required for the redispersion for further uses. Two possible mechanisms 
could attribute to: i) steric stabilization (formation of steric hindrance among 
particles) and ii) electrostatic stabilization (generation of higher repulsion forces 
between the dispersed particles). For sucrose, steric stabilization might be more 
dominant reason to yield less negative ZP after freeze-drying.  
The ZP of the NPs before freeze-drying demonstrated more negative charge 
due to presence of PVA residues and drug exposed to the surface. Using 
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cryoprotectant may be able to neutralize those unwanted residues leading to 
desirable less negative ZP after freeze drying. Compared to very high positive and 
negative surface charge, NPs with moderate negative or neutral surface charge have 
been found with higher residence time in the tumor and with lower phagocytic rate 
during the circulatory system (115). Therefore, we decided to continue using 
cryoprotectant for future studies to benefit from both the suitable size and tumor 
uptake. 
Drug loading efficiency was reached to 85% for certain drug loaded 
formulations; and amount of drug loaded per mg of NPs reached to 30%. TmAb 
modified NPs were found in a desired size range (below 400nm) with suitable PDI 
and ZP. Relatively less positive surface charges of modified NPs could be 
considered as neutral charged NPs, which may be able to avoid nonspecific 
electrostatic binding with the cells. Covalent attachment between NP and TmAb 
through cross-linking agent was found to be prominent. Using increased amounts of 
cross-linking agent in the formulation was unable to enhance the TmAb attachment 
with NPs. During emulsification process, aqueous phase could be saturated with 
maximum amount of BS3 (1.5 mg) and thus, excess amount of BS3 (over 1.5 mg) 
could be precipitated during solvent evaporation process. In addition, masking of 
BS3 may take place when excess amount of BS3 was used in the NP formulations. 
This may result in insufficient terminal spacer arms available to bind with TmAb. 
However, the maximum TmAb attachment efficiency was found in a range 50% to 
60%. 
HER2 overexpressed cells showed a promising cellular uptake of Coum-6 
loaded NPs compared to HER2 moderate expressed cells. Targeting efficiency of 
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TmAb was evaluated by preincubating both HER2 dependent cells with TmAb 
before Coum-6 loaded NPs treatment. Confocal images confirmed the clear cellular 
localization of dye loaded NPs. Covalently attached TmAb modified NPs showed 
comparatively better cellular internalization compared to physically adsorped TmAb 
modified and TmAb free plain NPs. 
Both HER2 dependent cell types after the treatment with different NP 
formulations showed different levels of HER2 expression and chemotherapeutic 
responses. The response was proportionally associated to the abundance of 
extracellular HER2 receptors on the cell types. A significant reduction for the level 
of HER2 expression was observed for targeted drug loaded NPs in HER2 
overexpressed SKBR-3 cells. The level of HER2 expression upon NPs treatments 
was also visually investigated with the images obtained using fluorescence 
microscope. 
 The evaluation of chemotherapeutic responses upon treating both cells with 
different formulations was comparatively analyzed based on the percentages of cell 
viability, cell death, apoptosis, and necrosis. Both cell types showed higher 
percentage of cell death as well as early apoptosis for free drug treatment compared 
to other treatment groups. The cell viability was higher for the untreated cells in both 
cell types and was comparable with the treatment of cells with Herceptin
®
 and the 
free TmAb. Compared to free drug treatment alone, drug loaded TmAb modified 
and unmodified NPs showed insignificant early apoptotic rate, which could be 
attributed to the lack of proper release of drug from the NP matrix. Notably, a clear 
chemotherapeutic effect was observed for the presence of TmAb in the NP 
formulations althouth the results were not significant. 
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Overall, the in vitro data using TmAb modified Doc loaded NPs have 
demonstrated a prospective potential to be applied as targeted chemotherapy against 
HER2 overexpressed breast cancer.   
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8. FUTURE DIRECTIONS AND RECOMMENDATIONS 
 
The primary in vitro results shown above clearly indicate that the TmAb 
functionalized Doc loaded PLGA NPs are capable platforms for HER2 positive 
breast cancer treatment. Although such NPs showed a potential for targeted 
chemotherapy over the chemotherapeutic drug alone, some future directions and 
recommendations may be considered to achieve better outcomes.  
1. The competency of biodegradable polymeric NPs for targeted delivery depends 
on the modification of size and surface charge of NPs. Surface 
functionalization of NPs with a suitable ligand tends to increase the size above 
the desired range, which could impede the internalization. To reduce the size 
of modified NPs, Fab fragment or single chain Fab (scFab) fragment could be 
functionalized avoiding the Fc fragment of whole mAb. 
2. Structural integrity and retaining encoded action are important factors for 
targeting ligand. Here, TmAb was extracted from the clinical formulation 
Herceptin
®
. Although covalent conjugation between BS3 and TmAb was 
investigated and confirmed using FTIR and SDS-PAGE, it was not observed 
whether the extracted TmAb retained the similar structural integrity as it was 
formulated with other excipients in Herceptin
®
. New method could be 
considered to investigate this parameter before applying in further 
experiments.    
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3. In the study, the amount of TmAb attachment to the NPs was low, which could 
be attributed to the lack of sufficient crosslinking agents embedded onto the 
NP surface. To overcome this issue, other possible conjugation methods can be 
used to achieve higher Ab attachment. By enhancing the TmAb attachment, the 
amount of NPs can be reduced for the treatments with the cell lines. 
4. Ester terminated PLGA was used to prepare the targeted NPs in this study. 
However, COOH terminated PLGA can be used for better TmAb attachment 
through EDC/NHS covalent conjugation process.  
5. BS3 inclusion as crosslinking agent in the NP formulation was observed with 
low drug loading and reduced TmAb attachment efficiency. In this case, the 
TmAb attachment process can be changed to yield more conjugation efficiency 
such as electrostatic bond. Because, the isoelectric point of Herceptin
®
 is 8.5 
that is positive in charge at acidic pH. The surface charge of NPs is negative in 
charge. A strong electrostatic bond could be formed between positively 
charged TmAb and negatively charged NPs.  
6. Treating cells with NP formulations with similar size and surface charge was 
not considered in this study. Maintaining similar size range and surface charge 
of all NP formulations could be served as better controls to assess the 
respective effects due to different treatment options. 
7. Balance between TmAb and loaded drug amounts in NPs could be made for 
desired treatment concentration. Because, no controls could be considered to 
treat the cells with specific amounts of drug loaded NPs or or vice versa. 
8. However, in vivo work should be undertaken to oberve the effects of whether 
our targeted chemotherapeutic NPs can efficiently reduce the size of tumor and 
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its HER2 expression with minimum side effects compared to free cytotoxic 
drug and TmAb. To evaluate its efficacy, evaluation of immune responses for 
this formulation and its related distribution throughout the body should be 
considered  in future investigations. 
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